1 
 
 
C. Clinical Protocol  
University  of Pi[INVESTIGATOR_392091], Surgery and Emergency Medicine  
MACRO ( Multidisciplinary Acute Care Research Organization)  
 
Study of Tranexamic acid during Air  and ground  Medical Prehospi[INVESTIGATOR_392092] (STAAMP) trial  
Phase 3 Multi -center, Prospective, Randomized, Blinded, Controlled Interventional Trial  
Protocol Version 2.7 date: January 11 , 2019  
 
 
 
 
This study is being funded by [CONTACT_2315] (DOD) Telemedicine and Advanced 
Technology Research Center (TATRC) . 
 
 
 
   
IND Sponsor:  Jason L. Sperry MD, MPH  
Associate Professor of Surgery and Critical Care Medicine  
University of Pi[INVESTIGATOR_9109]  
[ADDRESS_492523]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
[PHONE_8167]  
[EMAIL_7541]  
 
2 
 Table of Contents  
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ................................ ...........................  5 
A. Statement of Work  ................................ ................................ ................................ ................................ ..........................  6 
B. Investigators  ................................ ................................ ................................ ................................ ................................ .... 7 
Sub-Investigators and Key Study Personnel:  ................................ ................................ ................................ ......................  7 
Collaborating Centers and Site Principal Investigator s: ................................ ................................ ................................ ...... [ADDRESS_492524] -injury:  ................................ . 8 
C.2. Coagulopathy occurs early and is a complex, primary process following injury:  ................................ ........................  8 
C.3. Hyperfibrinolysis is associated with poor outcome following traumatic injury:  ................................ .........................  9 
C.4. Rapid -thromboelastography (TEG) and hyperfibrinolysis:  ................................ ................................ ..........................  [ADDRESS_492525] -injury:  ................................ ................................ ................................ .. 9 
C.6. Mechanisms responsible for the beneficial effects of tranexamic acid following injury remain inadequately 
characterized:  ................................ ................................ ................................ ................................ ................................ ... 10 
C.7. Plasmin and its pro -inflammatory effects:  ................................ ................................ ................................ ................  10 
C.8. Safety and dosing of tranexamic acid:  ................................ ................................ ................................ .......................  10 
C.9. Delay to definitive hemorrhage control:  ................................ ................................ ................................ ...................  11 
D. Preliminary Studies  ................................ ................................ ................................ ................................ ........................  11 
D.1. Addressing coagulopathy is associated with improved survival and reduction in blood transfusion requirements:
 ................................ ................................ ................................ ................................ ................................ ..........................  11 
D.2. Early attention to coagulopathy is associated with a reduction in massive transfusion:  ................................ .........  12 
D.3. Prehospi[INVESTIGATOR_392093]:  ................................ ................................ ................................ ................................ ................................ ................  12 
D.4. Feasibility of the trial:  ................................ ................................ ................................ ................................ ................  13 
D.5. Feasibility of air medical service intervention at the University of Pi[INVESTIGATOR_9109]:  ................................ ........................  13 
D.6. Clinical research infrastructure and coordinating center expertise of the University of Pi[INVESTIGATOR_9109]:  .......................  13 
D.7. Feasibility of patient recruitment for the trial:  ................................ ................................ ................................ .........  14 
E. Objectives/Hypotheses  ................................ ................................ ................................ ................................ ..................  14 
E.1. Study Rationale:  ................................ ................................ ................................ ................................ .........................  14 
E.2. Primary Objective:  ................................ ................................ ................................ ................................ ......................  [ADDRESS_492526] Milestones:  ................................ ................................ ................................ ................................ ........................  16 
G. Military Significance/Public Purpose:  ................................ ................................ ................................ ............................  16 
H. Research Design and Methods  ................................ ................................ ................................ ................................ ...... 16 
H.1. Study Design/Setting:  ................................ ................................ ................................ ................................ ................  16 
3 
 H.2. Study Population:  ................................ ................................ ................................ ................................ ......................  17 
H.3. Interventional Arm:  ................................ ................................ ................................ ................................ ...................  18 
H.4. Placebo/Control Arm:  ................................ ................................ ................................ ................................ ................  20 
H.5. Randomization:  ................................ ................................ ................................ ................................ ..........................  [ADDRESS_492527] Operating Procedures  ................................ ................................ ................................ ..............  21 
I. Outcome Variables/Definitions  ................................ ................................ ................................ ................................ ...... 21 
I.1. Primary Outcome  ................................ ................................ ................................ ................................ ........................  21 
I.2 Secondary Clinical Outcomes  ................................ ................................ ................................ ................................ .......  21 
I.3. Secondary Laboratory/Mechanistic Outcomes:  ................................ ................................ ................................ .........  21 
I.4. Clinical Outcomes Methods/Definitions:  ................................ ................................ ................................ ....................  21 
I.5. Laboratory/Mechanistic Outcome  Methods/Definitions  ................................ ................................ ...........................  23 
J. Analysis Plan:  ................................ ................................ ................................ ................................ ................................ .. 24 
J.1. Data Analysis for Pr imary Outcome  ................................ ................................ ................................ ............................  24 
J.2. Analysis of Prehospi[INVESTIGATOR_392094]  ................................ ................................ .......................  24 
J.3. Analysis for Second Stage In -hospi[INVESTIGATOR_392095] ................................ ................................ .......  25 
J.4. Predefined Subgroup Analyses  ................................ ................................ ................................ ................................ ... 25 
J.5. Randomization of Ineligible Subjects:  ................................ ................................ ................................ .........................  25 
J.6. Non -adherence  ................................ ................................ ................................ ................................ ...........................  25 
J.7. Missing Data  ................................ ................................ ................................ ................................ ...............................  25 
K. Sample Size Justification and Power Analysis:  ................................ ................................ ................................ ...............  25 
K.1. Primary Outcome 30 day mortality  ................................ ................................ ................................ ...........................  25 
L. Human Subjects:  ................................ ................................ ................................ ................................ ............................  26 
M. Screening, Enrollment and Notification:  ................................ ................................ ................................ ......................  26 
N. Data  ................................ ................................ ................................ ................................ ................................ ...............  27 
N.1. Sources  ................................ ................................ ................................ ................................ ................................ ...... 27 
N.2. Prehospi[INVESTIGATOR_392096]  ................................ ................................ ................................ ..........................  27 
N.3. In -Hospi[INVESTIGATOR_392096]  ................................ ................................ ................................ ...........................  27 
N.4. Data Entry  ................................ ................................ ................................ ................................ ................................ .. 28 
N.5. Database Management  ................................ ................................ ................................ ................................ .............  28 
N.6. Mortality Outcome Data (30 day)  ................................ ................................ ................................ .............................  [ADDRESS_492528] (DSMB)  ................................ ................................ ................................ ......................  28 
P.2.  Research Monitor  ................................ ................................ ................................ ................................ ......................  29 
P.3. Assessing and Reporting Adverse Events (AEs)  ................................ ................................ ................................ .........  29 
P.4. Interim Analyses  ................................ ................................ ................................ ................................ .........................  29 
P.5  IP Stoppi[INVESTIGATOR_1869]:  ................................ ................................ ................................ ................................ .......................  31 
Q. Quality Control and Assurance ................................ ................................ ................................ ................................ ...... 31 
Q.1. Protocol Compliance and Reporting  ................................ ................................ ................................ .........................  31 
Q.2. Investigator Responsibilities  ................................ ................................ ................................ ................................ ...... 31 
R. Study Limitations:  ................................ ................................ ................................ ................................ ..........................  32 
Bibliography  ................................ ................................ ................................ ................................ ................................ .......  32 
Clinical Protocol Appendix 2  ................................ ................................ ................................ ................................ ..............  36 
Clinical Protocol Appendix 3 – Data Safety Monitoring Board (DSMB) Charter  ................................ ................................  38 
Clinical Protocol Appendix 4 – Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ ..................  49 
 
5 
 PROTOCOL SYNOPSIS  
Study of Tranexamic acid d uring Air and ground Medical Prehospi[INVESTIGATOR_392092] ( STAAMP ) trial  
PI – Jason L. Sperry MD, MPH, Co -PI- Frank X. Guyette MD, MS, MPH  
Background: Traumatic ally injured patients continue to be plagued with uncontrolled hemorrhage resulting in 
significant morbidity and early mortality. A primary driving force for this unbridled hemorrhage is known to be 
the early coagulopathy which complicates severe injury. Traum a induced coagulopathy has been postulated to 
be an equilibrium imbalance between pro and anticoagulant factors, platelets, endothelium and fibrinolysis soon 
after injury. Recent evidence demonstrates that the early use of the antifibrinolytic agent tranex amic acid  (TXA)  
after trauma center arrival results in improved survival in patients at risk for bleeding. Bringing this proven 
treatment to the prehospi[INVESTIGATOR_392097], 
improve clinical outcomes and provide insight into the underlying mechanisms responsible for and which 
maximize its benefit.  
Objective/Hypothesis: The primary hypothesis will be that prehospi[INVESTIGATOR_392098]  [ADDRESS_492529] -injury.  
Specific Aims:  
Aim#1 : Determine whether prehospi[INVESTIGATOR_392099] a lower incidence of 
30 day mortality, 24 hour mortality, acute lung injury, multiple organ failure, nosocomial infection and 
improved shock parameters and early resuscitatio n and transfusion requirements.  
Aim#2 : Determine whether prehospi[INVESTIGATOR_392100] , 
lowers the incidence of acute traumatic coagulopathy and improves early markers of coagulopathy.  
Aim#3 : To explore novel  mechanisms by [CONTACT_392301][INVESTIGATOR_392101], plasmin 
levels and plasmin mediated complement activation and the early c ytokine response to trauma.  
Aim#4:  Determine whether different dosing regimens of tranexamic acid upon arrival in the hospi[INVESTIGATOR_392102], coagulopathy, clinical outcomes and the early inflammatory 
response.  
Study  Design : Multi -center, prospective, randomized, blinded, controlled interventional trial over 3 years 
focusing on patients with concern for bleeding who are transported via emergency  medical transport to 
definitive care.  
Population : Blunt or penetrating injured patients transported via emergency medical transport within two hours 
of estimated time of injury with  concern for bleeding with 1.) a documented systolic blood pressure < 90 mmHg 
at the scene, en route , or at outside/referral facility OR 2.) documented tachycardia (> 110 bpm) at the scene, en 
route , or at outside/referral facility. Stage 1 Intervention : 1gm of tranexamic acid or placebo will be infused in a 
100ml saline bag by [CONTACT_392302] 10 minutes once inclusion criteria are met. 
Prehospi[INVESTIGATOR_392103]. Stage 2 Intervention : 
After arrival enrolled patients who received tranexamic acid will undergo a second  randomization to one of 
three different arms: 1.) repeat tranexamic acid dosing, 2.) standard dosing or 3.) abbreviated dosing. Placebo 
infusion bags will be used for blinding in all arms  including those who received placebo for the Stage 1 
Intervention . Patients and all treatment staff will be blinded to the intervention arm given for both stages. 
Randomization : Predetermined randomized  allocation sequences using block sizes of 8 and 9 respectively for 
stage 1 and stage 2 interventions will be utilized.  
Relevance: Few interventions exist that alter the morbidity and mortality that inherently follows traumatic 
injury. By [CONTACT_392303][INVESTIGATOR_392104] a cascade of consequences with positive effects, in a cohort 
[ADDRESS_492530] and will promote focus on the mechanisms responsible and the dosing 
requirements of tranexamic acid that maximize its benefit.  
 
 
CLINICAL PROTOCOL  
 
A. Statement of Work  
Principal Investigators (PIs) : [CONTACT_392360] L. Sperry and [CONTACT_311272] X. Guyette will oversee all planning and 
execution of the Study of Tranexamic acid during Air Medical Prehospi[INVESTIGATOR_392092] (STA AMP) trial which is a 
3 year, multi -center, randomized, double blinded, placebo controlled clinica l trial. For patients at risk of 
bleeding who are transported by [CONTACT_392304], a 1 gram bolus of prehospi[INVESTIGATOR_392105], 
coagulation, in flammatory and dosing regimen endpoints.  
Coordinating Center : The University of Pi[INVESTIGATOR_392106]. The University of Pi[INVESTIGATOR_392107] r the 
education and training of participating center research staff and will oversee education and training of 
prehospi[INVESTIGATOR_392108]. The University of Pi[INVESTIGATOR_392109] s will be responsible for sample acquisition, sample storage, data 
acquisition and entry via web based platform, and maintenance of data integrity.  
Participating Centers : Site Investigators from participating centers will oversee the planning and execution  of 
the trial at their respective centers.  
The Principal Investigators, the University of Pi[INVESTIGATOR_392110]:  
1. Determine whether prehospi[INVESTIGATOR_392111]  30 day mortali ty, 
reduces  the incidence of hyperfibrinolysis, Acute Traumatic Coagulopathy and improves early markers 
of coagulopathy and hyperfibrinolysis. (r -TEG parameters, D -dimers, activated protein C, and plasmin -
anti-plasmin complexes)  
2. Determine whether prehospi[INVESTIGATOR_392099] a lower incidence of 
24 hour mortality, acute lung injury, multiple organ failure, nosocomial infection, shock parameters, 
early resuscitation and transfusion needs, early seiz ures and pulmonary embolism.  
3. To explore potential novel mechanisms by [CONTACT_392305], me asurements of plasmin levels and subsequent plasmin mediated complement 
activation and the early inflammatory cytokine response to trauma.  
4. Determine whether different dosing regimens of tranexamic acid upon arrival in the hospi[INVESTIGATOR_392112], markers of coagulopathy, clinical outcomes, and the 
early inflammatory response.  
Pre Trial Start Period : The PIs and Site investigators will obtain FDA approval followed by [CONTACT_392306]. The University of Pi[INVESTIGATOR_392113] a web based data entry platform for the trial.  
 
Year 1 : Following a [ADDRESS_492531] interim analysis will occur at 1/3 of total patient enrollment. Those 
exploratory aim measurements that  require fresh blood samples will occur at the University of Pi[INVESTIGATOR_392114].  
 
Year 2 : An estimated additional 330 patients will be enrolled (total=660 ) by [CONTACT_392307]. Continued prospective data collection and 
integrity verification for cl inical outcomes will occur. A second interim analysis will occur after 2/3 of total 
patient enrollment. Exploratory aim measurements which require fresh blood samples will occur at the 
University of Pi[INVESTIGATOR_392115].  
 
Year 3 : An estimated additional 334 pa tients will be enrolled (total=994) by [CONTACT_392308], blood samples 
will be batched for analysis. Continued prospective data collection and integrity verification for clinical 
outcomes will occur. Exploratory aim measurements which require fresh blood samples will occur at the 
University of Pi[INVESTIGATOR_392115]. Study completion, final manuscript preparation will soon follow.  
 
B. Investigators  
 
 
Principal Investigator:  [INVESTIGATOR_65148] L. Sperry MD, MPH , Associate  Professor of Surgery and Critical Care 
Medicine, Co-Director of Acute Care Fellowship , University of Pi[INVESTIGATOR_392116]-Investigators  and Key Study Person nel: 
 
Co-Investigator s:  Frank X. Guyette MD, MS, MPH ; Brian S. Zuckerbraun  MD; Clifton 
Callaway, MD, PhD;  Graciela Bauza, MD; Raquel Forsythe, MD; Juan C. 
Puyana, MD; Gregory Watson, MD; Ankur Doshi, MD; Scott Gunn, MD; 
Christian Martin -Gill, MD; Paul Phrampus, MD; Matthew Rosengart, MD; 
Matthew Neal, MD; Barbara Early, RN, BSN , Adam Janicki, MD; Joseph 
Yanta, MD; Adam Frisch, MD; Aaron Brown, MD ; Anthony Pi[INVESTIGATOR_392117], MD ;  
Joshua Shulman, MD ; Adam Tobias, MD, MPH; Julie McCausland, MD; 
Alexandra Castro, MD; Charissa Pacella, MD ; Amy Talley, MD; Ross 
McCormack, MD                                                                                                                                                
 
Consultant :  Mazen Zenati MD , MPH, PhD , Assistant Professor of Surgery and 
Epi[INVESTIGATOR_623], University of Pi[INVESTIGATOR_392118]:    Derek C. Angus MD, MPH, The Mitchell P. Fink Professor and Chair,   
    Department of Critical Care Med icine, University of Pi[INVESTIGATOR_392118]:  Timothy R. Billiar MD , George Vance Foster Professor and Chair, Department 
of Su rgery, University of Pi[INVESTIGATOR_392118]:  Alan D. Murdock MD, Chief  of Acute Care Surgery, Department of Surgery, 
University of Pi[INVESTIGATOR_9109] , Consultant to the Surgeon General for Trauma/Critical 
Care, Air Force Medical Operations Agency  
Consultant:  Andrew B. Peitzman MD , Mark M. Ravitch Professor  and Vice -Chair, 
Chief, Division of General Surgery, University of Pi[INVESTIGATOR_392119]:   Louis Alarcon, MD , Medical  Director, Trauma Surgery ; Associate  Professor of  
    Surgery and Critical Care, University of  Pi[INVESTIGATOR_392120]:  
 
8 
 University of Arizona : Gary Vercruysse,  MD,  Medical Director, Burn Care Program, 
Associate Professor of Surgery , University of Arizona  
University of [LOCATION_007], San Antonio :   Brian J. Eastridge MD, Chief of Trauma Services, Professor -
Clinical, Department of Surgery, University of [LOCATION_007] at San 
Antonio  
University of Utah : Raminder Nirula MD, MPH, Associate Professor of Surgery, 
Surgical Critical Care Fellowship Director , University of Utah  
C. Background  and Significance  
C.1. Uncontrolled hemorrhage and coagulopathy remain leading causes of mortality  post-injury : 
Hemorrhage is est imated to be responsible for over 40% of  all trauma -related deaths, nearly half of which occur 
in the pre-hospi[INVESTIGATOR_6885] .1,2 Uncontrolled bleeding remains the leading cause of early in hospi[INVESTIGATOR_34380].3,4 
Ongoing h emorrh age is  complicated by [CONTACT_65357] -known ‘lethal triad’  of coagulopathy, hypothermia and acidosis  
(Fig 1 .).5-[ADDRESS_492532] been proposed and studied , interventions 
that reduce the morbidity and mortality associated with hemorrhage and coagulopathy in the clinical arena 
remain limited.13,14  
C.2. Coagulopathy  occurs early  and is a complex, primary  
process  following injury:  Coagulopathy has been shown to be  
present in over 25% of patients at the time of trauma admission 
and has been determined to be  an independent predictor of 
mortality  with an associated [ADDRESS_492533] dysfunction or consumption of 
coagulation factors , may be to o simplistic.23 More recent evidence demonstrates the importance of shock and 
tissue hypoperfusion as principle drivers of coagulopathy  following injury  which  results in an imbalance of the 
equilibrium between procoagulant factors, anticoagulation factors, platelet and leukocyte activation, and 
fibrinolysis .12,20,23-26 (Fig 2 .) As our understanding has increased regarding the mechanisms responsible for the 
acute coagulopathy of trauma, a new paradigm where early coagulopathy post -injury is considered a complex, 
multi -factorial, primary event has developed.22,23,[ADDRESS_492534] time 
period and in those patients who would otherwise not be candidates for treatment due to th e early 
time requirements for its administration  . 
Ongoing  
Hemorrha
ge 
‘Lethal 
Triad’  
Acidosis  
 Hypothermia  
Coagulopathy  
Fig 1. Adapted from Jansen JO, et al. BMJ . 2009 Jun 5;338:b1778  
9 
 C.3. Hyperfibrinolys is is associated with poor outcome  
following traumatic injury : Hyperfibrinolysis has  been 
identified as an integral component of acute traumatic 
coagulopathy .28,29 The incidence of hyperfibrinolysis  as 
measured by [CONTACT_392309] (TEG)  has been 
identified in 2% to 34% of trauma patients , with those 
patients who require  large volume transfusion (>[ADDRESS_492535] 6 hours) having the highest incidence.29-31 It has 
been shown to occur early , following  traumatic  injury and 
significantly associated with  an independent greater  risk 
of mortality,  the need for massive transfusion , higher 
injury and shock severity , and greater prehospi[INVESTIGATOR_392121].29-32 Importantly, recent evidence 
suggests moderate fibrinolysis,  as measured by [CONTACT_392310] -antiplasmin complexes in serum, may be 
apparent in over 50% of patients.[ADDRESS_492536] TEG analysis, but is associated again with significantly greater 28 -day 
mortality, greater ICU requirements and longer length of stay.  
C.4. Rapid -thromboelastography (TEG) and h yperfibrinolysis : As we continue to expand  our 
understanding of the acute coagulopathy of trauma, emphasis has also been placed on diagnosing coagulo pathy 
which complicates injury to allow real time assessment to guide 
evolving blood component transfusion requirements.33 Increasing 
evidence suggests that historic reliance on prothrombin time (PT), 
and international normalized ratio (INR)  is time exclusive and 
provides insufficient information  relative to the complexity which 
drives this coagulopathic process.34-36 Needed for  the appropriate 
evalu ation of an acutely injured patient ’s coagulation status is a 
rapid, reliable assessment of the thrombosis and fibrinolysis arms 
of the hemostatic cascade . Thromb oelastography (TEG)  is a 
technology which  provide s a real time, viscoelastic analysis of 
these blood clotting process es.33 (Fig 3 .) Point -of-care rapid 
thromb oelastography (POC r -TEG) differs from standard TEG 
because the clotting process and subsequent anal ysis is accelerated 
by [CONTACT_392311] a whole blood sample.[ADDRESS_492537]-injury : 
In a large, civilian, multicenter, randomized, controlled trial (CRASH -2 trial) on the use of tranexamic acid in 
patients at risk of bleeding, a significant reduction in mortality was found  with its use .41 Tranexamic acid is a 
lysine analog that is known to interfere with bin ding sites on plasminogen and inhibit fibrinolysis.42 Inclusion 
criteria for the trial included hypotension SBP <90 mm Hg or tachycardia (> 110 beats per min), in patients at 
risk of significant hemorrhage  within 8 hours from injury . Dosing of tranexamic acid was given in a bolus 1 
gram dose over approximately 10 minutes followed by [CONTACT_392312] (additional 1 gram) over eight hours. 
This therapy was  subsequently found  in exploratory analysis  to be benef icial in those who received tranexamic 
acid in the first [ADDRESS_492538] TEG parameters.  Reaction (R) time, clot 
formation (K) time, fibrin cross -linking (angle = α), clot 
strength (maximal amplitude [MA]), and estimated percent lysis 
(EPL). Harr JN,et al. J Surg Res . [ADDRESS_492539];170(2):319 -24. 
Fig 2. Nascimento B. et al. Crit Care. 2010; 14(1): 202.  
[ADDRESS_492540] severely injured.44  Importantly, 
subgroup analysis on patients with brain injury revealed neither moderate benefits nor moderate detrimental 
effects and provides grounds for further evaluation  in those patients with traumatic brain inj ury.45 Military 
experience with tranexamic also has demonstrated beneficial effects in a large retrospective analysis  
(MATTERs) study .[ADDRESS_492541] laboratory testing 
(prothrombin time or activated partial thrombopla stin time).  Importantly, no information regarding the potential 
benefits of pre -hospi[INVESTIGATOR_392122].  
C.6. Mechanisms responsible for the beneficial effects  of tranexamic acid  following injury remain 
inadequately characterized : Tranexamic acid is known to inhibit fibrinolysis and has most commonly been 
used to decrease blood loss during cardiac  and orthopedic su rgeries.47-[ADDRESS_492542].41 Early coagulopathy measurements or TEG analysis to measure fibrinolysis 
were not performed while only 50% of enrolled patients required blood transfusion at all.46 In the trial, total 
blood transfusion was recorded along with operative procedures, with neither of these important outcomes 
being different across treatment groups (tranexamic acid vs. placebo). Early blood transfusion requi rements in 
the first [ADDRESS_492543], were not recorded. In the 
retrospective military study (MATTERs) tranexamic acid was associated with greater  [ADDRESS_492544]  outcome via a non -antifibrinolytic mechanism.   
The successful completion of the proposed aims of the current proposal will provide needed insight 
into the  mechanisms responsible for the mortality benefit attributable to tranexamic acid in patients 
at risk for hemorrhage  including those with brain injury , allowing focus on specific pathways and 
future therapeutic targets that will further improve care of the injured patient.  
C.7. Plasmin and its pro-inflammatory effects : Tranexamic acid is a lysine analogue that interferes with 
binding of plasminogen to fibrin, which is required for plasmin activation.[ADDRESS_492545] due to a reduction in plasm in activation. ( Fig 4 .) 
C.8. Safety and dosing of  tranexamic acid : Tranexamic acid has been  most  commonly used in cardiac surgery 
and orthopedic surgery for its blood transfusion reduction effects  with the  risks of thrombotic comp lications and 
post-operative seizures being the most common complications 
reported  with its use .49,50,56,[ADDRESS_492546] that f urther higher level studies are 
Fig 4. Pro -inflammatory and coagulation system effects of 
plasmin. Levy JH. Lancet.  2010 Jul 3;376(9734):3 -4 
 
11 
 required to verify the safety profile of lysine analogue anti-fibrinolytics in the non -injured patient 
population.49,60 The CRASH -2 trial , which looked at over 20,000 patients  demonstrated  no differences in deaths 
from vascular occlusive events including myocardial infarction, stroke, and pulmonary embolism  and concluded 
the tranexamic acid safely reduced the risk of death in bleeding trauma patients.41 Importantly, the trial 
demonstrated that mortality due to bleeding was increased in patients who received tranexamic acid beyond 3 
hours from injury.43  In the retrospective military study (MATTERs, 896 patients) an increase d incidence of 
deep vein thrombosis and pulmonary thromboembolism was demonstrated. These results were , however,  
confounded by [CONTACT_392313].[ADDRESS_492547] been 1 to 2 grams either in loading  and/or  infusion 
route , all within the first 8 hours from injury.  For the CRASH -2 trial, the dosage regimen was selected to 
provid e a fixed dose within the range shown to inhibit fibrinolysis in larger patients and safe in smaller patients 
(10 mg/kg loading and 1mg/kg/hr infusion dose).[ADDRESS_492548] safe and optimal dosing regimen in trauma patients  at risk for bleeding remains obscure .60 
C.9. Delay to definitive hemorrhage control:  Definitive control of ongoing hemorrhage remains a 
fundamental p rinciple in trauma management. Increasing attention has been paid to the significance of delay 
and the timing of definitive control of hemorrhage. Clarke and colleagues have previously shown that delays to 
operative intervention in patients with significan t abdominal injuries are associated with a higher mortality risk, 
demonstrating a 1% higher risk of mortality for every [ADDRESS_492549] . 
 
D. Preliminary Studies  
D.1. Addressing coagulopathy is associated with improved survival 
and reduction in blood transfusion requirements:  Secondary  to the  
University of Pi[INVESTIGATOR_9109]’s participation with the Inflammation and the Host 
Response to Injury Large Scale 
Collaborative Program prospective 
cohort trial, (www.gluegrant.org ), we 
have previously characterized the 
relationships of addressing the early 
coagulopathy following acute injury 
and the outcomes associated with its 
presence.69-[ADDRESS_492550] documented 
the relationship between high fresh 
frozen plasma:packed red blood cell 
(FFP:PRBC) transfusion ratios in 
Fig 5. Kaplan -Meier Survival Analysis comparing 
survival across different transfusion ratio groups.  
0.0324HR Mortality12HR Mortality6HR MortalityPLT:PRBC24HR Mortality12HR Mortality6HR MortaltiyFFP:PRBC
1.[ADDRESS_492551] injury.  
Fig 6. Transfusion requirements across High and 
Low FFP:PRBCs groups  
12 
 massive transfusion patients and outcome.74 We verified a dose response relationship revealing as the 
FFP:PRBC increased toward 1:1.5, a significant reduction in mortali ty occurred. ( Fig 5 .) Equally important, 
there were significant reductions in blood and blood component transfusion requirements in those with High vs. 
Low FFP:PRBC transfusion ratios. ( Fig 6 .) More recent analyses aimed to debunk any question of survival bias 
regarding high plasma transfusion ratios in the glue grant cohort.[ADDRESS_492552] regression was used to 
determine the independent mortality risks at 6hr, 12hr, and 24hrs while controlling for important confounders. 
FFP:PRBC and platelet:PRBC ratios were also analyzed as time -dependent covariates  accounting for 
fluctuation o ver time. We found that despi[INVESTIGATOR_392123], HIGH 
FFP:PRBC and platelet:PRBC ratios are associated with a survival benefit as early as 6hrs and throughout the 
first 24hrs, even when time dependent fluctuations of compone nt transfusion were accounted for. ( Fig 7.)  We 
concluded that the observed mortality benefit associated with high component transfusion ratios was unlikely 
due to survivor bias and that early attainment of high transfusion ratios may significantly lower th e risk of 
mortality in MT patients . This prior work demonstrates that addressing the coagulopathy following significant 
injury is associated with improved outcome.  
D.2. Early attention to coagulopathy  is associated with a reduction in massive transfusion:  We have 
recently characterized changes in resuscitation practice which have occurred over time in a cohort severely 
injured patients requiring massive transfusion.73 We demonstrated that the incidence of massive transfusion 
(>10 units blood) significantly decreased over time, 
despi[INVESTIGATOR_392124]. ( Fig 8 .) 
When  the recent time period (2007 -current) wa s 
compared to the early time period (2004 -2006) of enrollment 
for the study, there was a significant increase in the 
FFP:PRBC and platelet:PRBC transfusion ratios  
as early as [ADDRESS_492553] 6hrs relative to the 
total give at 24 hours significantly increased. ( Fig. 9 .) 
This occurred in patients who required [ADDRESS_492554].  
D.3. Prehospi[INVESTIGATOR_392125] : 
Secondary to the University 
of Pi[INVESTIGATOR_9109]’s participation with the Resuscitation Outcomes Consortium  
(https://roc.uwctc.org/ ), prior work has demonstrated the importance of 
interventions i n the prehospi[INVESTIGATOR_392126] .75-[ADDRESS_492555] also previously 
demonstrated the expertise th e air medical  service has with air medical 
interventions  in injured patients .80-82 A recent analysis d emonstrates the 
importance of prehospi[INVESTIGATOR_392127] -hospi[INVESTIGATOR_39473], need for emergent operative intervention and the 
2004 2006 [ZIP_CODE].05.06.07.020253035MT (%  patients)
ISS
*
*Median 24hr PRBC (unit)
*
YearFig 8. Decreasing incidence of massive transfusion  over time 
with increasing injury severity  
FFP PLT304050607080EARLY
RECENT
* *SUB-MT 6HR/24HR %
Fig 9. Comparing the proportion of component 
transfusion in the first 6 hours relative to 24 hours 
in early and recent time periods.  
Fig 10. Logistic regression results for prehospi[INVESTIGATOR_392128] -hospi[INVESTIGATOR_39473], need 
for emergent operation and multiple organ failure.  
13 
 development of multiple or gan failure.83 (Figure  10.) More recent work demonstrates the utility of air medical 
tissue oximetry and the ability it has to predict operat ive intervention or blood transfusion in the first 24 hours 
following injury.84 (Figure 11 .) A recent study  which was presented at the [ADDRESS_492556] annual meeting utilizing 
Gluegrant dataset demonstrated that overly aggressive prehospi[INVESTIGATOR_392129] (SBP> 
90mmHg) while a t rend towards benefit and lower risks of poor outcome were found in patients with 
prehospi[INVESTIGATOR_392130] (SBP<90mmHg). (Journal of Trauma and Acute Care Surgery. In Press , 2013 , Figure 
12.)  
D.4. Feasibility of the trial:  The collaborative environment between the 
Departments of Surgery  and Emergency Medicine at the University of 
Pi[INVESTIGATOR_392131].  The principal 
investigators participation and involvement in the Inflammation and the 
Host  Response to Injury Program, ( Glue grant ), the Resuscitation 
Outcomes Consortium ( ROC ) and recent funding (proposal #11152002, 
W81XWH -12-2-0023) from the Department of Army for the  ‘Prehospi[INVESTIGATOR_392132] (PUPTH) Program’ documents  
and verifies the robust nature of the University of Pi[INVESTIGATOR_9109]’s multi-center 
research collaborations and expertise in prehospi[INVESTIGATOR_392133],  the 
clinical research infrastructure  that is available and the institutional and 
departmental support to promote and allow the successful execution and 
completion of the propo sed aims that will  provide important knowledge 
into the mechanisms and appropriate dosing of tranexamic acid that 
maximize its beneficial effects.  
D.5. Feasibility of air medical service intervention  at the University 
of Pi[INVESTIGATOR_9109] : Under the direction of [CONTACT_392361], Co -Principal 
Investigator [INVESTIGATOR_392134], the air medical service  at the University of 
Pi[INVESTIGATOR_392135] -profit flight service in the country and  has a 
significant track record of prospective trials and interventions  in the 
prehospi[INVESTIGATOR_392126] .76,78,79,82-[ADDRESS_492557] 12 months (2012 
data). The DOD funded PAMPer trial (Prehospi[INVESTIGATOR_392136]) under the auspi[INVESTIGATOR_392137] [ADDRESS_492558] patient populations available 
across the country for a n air medical  prehospi[INVESTIGATOR_336501] . It is this extensive prehospi[INVESTIGATOR_392138] . 
D.6. Clinical research infrastructure and c oordinati ng center expertise of the University of Pi[INVESTIGATOR_9109] : 
The Department of Surgery at the University of Pi[INVESTIGATOR_392139] (MACRO). MACRO is a unique, 
interdepartmental resource with laboratory facilities, an experien ced and professionally -trained staff of [ADDRESS_492559] center model 
and provides ‘cost -neutral’ services to clinical investigators from diverse specialties in order to conduct clinical 
and translational researc h. Currently, Over 71 principal investigators and co -investigators from 9 different 
departments currently utilize MACRO services.  Thru 2012 alone, MACRO’s services were utilized for [ADDRESS_492560] -injury  
14 
 interventional trials and 11 observational trials. MACRO has been the c linical research infrastructure utilized 
for the institutions involvement in the  Gluegrant  and ROC  studies and is the infrastructure that is being utilized 
for the multi -center coordination of the DOD funded PAMPer trial.  It is with the dedicated clinical research 
infrastructure provided by [CONTACT_392314][INVESTIGATOR_392140].  
D.7. Feasibility of patient recruitment  for the trial : As demonstrated by  [CONTACT_392315] o f both 
the Gluegrant  and ROC  studies , the departments of Surgery and Emergency Medicine at the University of 
Pi[INVESTIGATOR_392141] a significant track record of successful patient recruitment and enrollment in large  prehospi[INVESTIGATOR_392142] . Regarding the specifics of the current proposal, over the 
last 12 months , the air medical service s that will be utilized for this trial  has transported > 150 patients  meeting 
the specific inclusion and exclusion criteria for this proposal ( SBP < 90mmHg  and tachycardia - > 110 bpm ). 
Participating centers have been chosen with similarly busy air medical services and with a history of 
involvement with the Gluegrant, ROC  or with other multi -institutional clinical research experience . It is under 
the auspi[INVESTIGATOR_392143].  
 
E. Objectives /Hypotheses  
E.1. Study Rationale:  Traumatic injured patients continue to be plagued with uncontrolled hemorrhage 
resulting in significant morbidity and early mortality. A primary driving force for this unbridled hemorrhage is 
known to be the early coagulopathy which complicates severe injury. Trauma induced coagulopathy has been 
postulated to be an equilibrium imbalance between pro and anticoagulant factors, platelets, endothelium and 
fibrinolysis soon after injury. Recent evidence demonstrates that the early use of the antifibrinolytic agent 
tranexamic acid after trauma center arrival results in improved survival in patients at risk for bleeding. Bringing 
this proven treatment to t he prehospi[INVESTIGATOR_392144], 
improve clinical outcomes and provide insight into the u nderlying mechanisms responsible for and which 
maximize its benefit.  
E.2. Primary Objective:  To determine the effect of prehospi[INVESTIGATOR_392145] (1 gram over 
approximately 10 minutes)  as compared to placebo during emergency  medical transport in patients at risk of 
traumatic hemorrhage on 30 day mortality.  
E.2.1. Primary Aim#1 : Determine whether prehospi[INVESTIGATOR_392111] 
30 day mortality  in patients at risk for traumatic hemorrhage . 
Primary Hypothesis 1 : Prehospi[INVESTIGATOR_392146] 30 day mortality  
in patients at risk of traumatic hemorrhage  
E.3. Secondary Objectives : To determine the effect of prehospit al tranexamic acid infusion (1 gram over  
approximately  10 minutes) as compared to placebo during emergency  medical transport in patients at risk of 
traumatic hemorrhage on the incidence of hyperfibrinolysis (estimated percent lysis > 7.5%, first 30 minutes  by 
[CONTACT_392316] -thromboelastography) acute traumatic coagulopathy (ATC), early markers of coagulopathy, the incidence 
of 24 hour mortality, acute lung injury, multiple organ failure and development of nosocomial infection, shock 
parameters and resuscitation/tran sfusion requirements, platelet and leukocyte activation and the early 
inflammatory response and to determine whether different dosing regimens of tranexamic acid upon arrival in 
the hospi[INVESTIGATOR_392147], coagulopat hy, clinical outcomes  and the 
early inflammatory response.  
E3.1.  Secondary Aim#1 : Determine whether prehospi[INVESTIGATOR_392148] (estimated percent lysis > 7.5%), acute traumatic 
coagulopathy (ATC, presenting INR > 1.4) , improves P T measure ments and additional r -TEG 
parame ters, D -dimer levels, activated Protein C levels, and plasmin -antiplasmin complexes.  
15 
 Secondary Hypothesis 1 : Prehospi[INVESTIGATOR_392149] (estimated percent lysis > 7.5%), reduce the inciden ce of pat ients with an arrival INR 
> 1.4,  improv e PT and  additional presenting r -TEG parameters of coagulopathy including ACT, r -value, 
k-time, α -angle, maximal amplitude (MA) and G -values and D -dimer  levels , activated Protein C levels  
and plasmin -antiplasmin complexes.  
E.3.2. Secondary  Aim#2 : Determine whether prehospi[INVESTIGATOR_392150] a lower incidence of 24 hour mortality, acute lung injury, multiple organ failure, nosocomial 
infection,  early seizures, pulmonary embolism,  shock parameters and early resuscitation and transfusion 
requirements . 
Secondary Hypothesis 2A : Prehospi[INVESTIGATOR_392151] 24 hour and 30 day mortality, acute lung in jury, multiple organ failure,  nosocomial 
infection , early (24hr) seizures and in -hospi[INVESTIGATOR_392152] . 
Secondary Hypothesis 2B:  Prehospi[INVESTIGATOR_392153], 24 hour crystalloid requirements  and reduce 6 hour and 24 hour blood and blood 
component transfusion requirements (PRBC, FFP and platelets).  
E.3.3. Secondary Aim #3 : To investigate potential novel mechanisms by [CONTACT_392317]. Investigations of the 
effects of tranexamic acid on inflammation will include analysis of platelet and leukocyte activation via 
flow cytometry, measurements of plasmin levels and subsequent plasmin mediated complement 
activation and the early inflammatory cytokine response to trauma.  
Secondary Hypothesis 3A : Prehospi[INVESTIGATOR_392154] (FACS) and result 
in a plasmin mediated reduction of complement activation as measured by C3a and Factor B levels.  
Secondary Hypothesis 3B : Prehospi[INVESTIGATOR_392155] -
induced pro -inflammatory changes and immunosuppression  by [CONTACT_392318] (GM -CSF, IFN -γ, IL -1β, IL -2, IL -4, IL -5, IL -6, IL -8, IL -10 and TNF -α), HMGB1 
levels and early inflammatory gene responses as measured by [CONTACT_937]-PCR . 
E.3.4 . Secondary Aim#4 : Determine whether different dosin g regimens of tranexamic acid upon arrival 
in the hospi[INVESTIGATOR_392147], markers of coagulopathy , clinical 
outcomes, platelet and leukocyte activation and the early inflammatory response.  
Secondary Hypothesis 4A : Repeat dosing of [ADDRESS_492561]  already received 1 gram of  prehospi[INVESTIGATOR_392156] 12 hour (from arrival) hyperfibrinolysi s (estimated percent 
lysis > 7.5 %), coagulopathy (INR > 1.4 ) and improve r -TEG markers of c oagulopathy , D-dimer  levels , 
activated protein C levels and plasmin -antiplasmin complex levels  as compared to standard dosing of 
tranexamic acid (1 gram over approxi mately 8 hours) or abbreviated dosing ( no additional tranexamic 
acid). 
Secondary Hypothesis 4B : Repeat dosing of [ADDRESS_492562] dosing or abbreviated dosing.  
Secondary Hypothesis 4C:  Repeat dosing of 1 gram of tranexamic acid followed by 1 gram over 
approximately 8 hours after hospi[INVESTIGATOR_392157]  12 hour (from arrival) base deficit, 24 hour crystalloid requirements and 6 hour and 24 hour 
blood and blood component transfusion requirements (PRBC, FFP and platelets) as compared to 
standard dosing or abbreviated dosing.  
Secondary Hypothesis 4D : Repeat dosing of 1 gram of tranexamic acid followed by 1 gram over 
approximat ely 8 hours after hospi[INVESTIGATOR_392158] 12 hour and 24 hour (from arrival) markers for platelet and leukocyte activation, plasmin 
[ADDRESS_492563] Milestones:  
The proposal is for a 3 year trial. The FDA approval process will be initiated after notification of proposal 
funding.  Community notification and other procedures associated with exception from consent for emergency 
research will be initiated and completed prior to IRB approval at all instituti ons. Following final IRB approval a 
1.5 month startup period will be utilized to verify and educate all centers prior to beginning enrollment. A data 
entry web based platform will be created during this same time period. Enrollment will occur for 33 months  
(2.75 years) with prospective data entry of laboratory and TEG measurements, clinical outcomes, transfusion 
requirements and demographic and injury characteristics. Serum for cytokine and ELISA measurements will be 
batched and sent to the University of Pi [INVESTIGATOR_392159]. We expect approximately [ADDRESS_492564] (DSMB). 
Interim a nalysis will occur at 33% and 66% of patient enrollment. A 1.5 month data cleaning and wind down 
will occur once enrollment has been completed, allowing data analysis and manuscript preparation.  
 
G. Military Significance/Public Purpose:  
Despi[INVESTIGATOR_392160] -injury management practices which have 
occurred over the last decade, uncontrolled hemorrhage remains one of the leading causes of trauma related 
deaths.4,5,87,[ADDRESS_492565].  
 
H. Research Design and Methods  
H.1. Study Design /Setting : The study will be a [ADDRESS_492566] . For 
patients at risk of hemorrhage being transported by [CONTACT_392304], the infusion of 1 gram of 
tranexamic acid over  approximately  10 minutes in the prehospi[INVESTIGATOR_392161] .  The 
University of Pi[INVESTIGATOR_45589] (UPMC) will be both the clinical outcome and data coordinating 
center. Each individual institution will perform point of care rapid TEG analysis and coagulation measurements 
on site. UPMC presby[CONTACT_392319] -[ADDRESS_492567] no other clinical investigations that would preclude parti cipation in 
the current proposal . Participating Institutions include:  University of Pi[INVESTIGATOR_9109], University of Arizona , 
University of [LOCATION_007]  at San Antonio , and the  University of Utah . The University of Tennessee at Memphis will 
be utilized as an alternate /additional site if required.  
H.2. Study Population : The study population will include blunt or penetrating  injured patients at risk of 
hemorrhage  being transported via emergency  medical services from the scene of injury or from referring 
hospi[INVESTIGATOR_114682] a definitive trauma center  that is participating in the trial . We have selected similar inclusion criteria 
as the prior large, p rospective study41 (CRASH -2).   This represents a similar  level of acuity than the CRASH -2 
study and additionally allows the mechanism of tranexamic acid’s benefit to be characterized across  a spectrum 
of injury severity since the pre -specified analysis of the  CRASH -[ADDRESS_492568] severely injured.44  The study group may also contain 
traumatic brain injured patients who represent  a subgroup that may also benefit from early  tranexamic 
intervention . 45 Based upon our own current data  (2011 -2012) in injured patients that require air medical 
transport, these inclusion cri teria are associated with over a 65% blood transfusion rate in th e first [ADDRESS_492569] pertinent population for the trial . 
H.2.1. Specific Inclusion Criteria : 
1. Blunt or penetrating  injured patients at risk of hemorrhage being transported via emergency  medical 
services from the scene of injury or from referring hospi[INVESTIGATOR_114682] a definitive trauma center that is 
participating in the trial  
AND  
2. Within 2 hours of  estimated  time of injury  
AND  
3A. Hypotension (Systolic Blood Pressure (SBP) < 90mmHg)  
  i. At scene of injury or during emergency medical transport  
 ii. Documented at referring hospi[INVESTIGATOR_392162] 
3B. Tachycardia  (heart rate >110  beats per minute ) 
  i. At scene of injury or during emergency  medical transport  
  ii. Documented at referring hospi[INVESTIGATOR_392163]  
 
 
 
      H.2.2 Specific Exclusion Criteria : 
1. Age > 90 or < 18 years of age ; 2. Inability to obtain intravenous  or intraosseous  access ;3. 
Documented  (radiographic evidence)  cervical cord injury with motor deficit ; 4. Known p risoner ; 5. 
Known p regnancy ; 6. Traumatic arrest with > 5 minutes  CPR without return of vital signs ; 7. 
Penetrating cranial injury  8. Traumatic brain injury with brain matter exposed ; 9. Isola ted drowning or 
hanging victims   10. Wearing an opt out bracelet.  11. Objection to study voiced by [CONTACT_392320].  12.  Isolated fall from standing  
 
Inclusion  and exclusion  criteria will be assessed based on available information at the time of enrollment.  
Although all reasonable efforts will be made by [CONTACT_392321], including qualifying vitals, due to the nature of the emergency pre -hospi[INVESTIGATOR_111483], there may be occasions where the emergency  medical crew must rely on verbal report of qualifying 
vitals from the referring hospi[INVESTIGATOR_392164].  In these instances, if, after subsequent r eview of outside 
hospi[INVESTIGATOR_3491]/or ground crew documentation, it is determined that the subject did not meet inclusion criteria  
18 
 and/or met exclusion criteria , the subject will remain enrolled in the study based on the intention -to-treat 
principle.  
 
In the e vent that a verbal report must be used in lieu of physical documentation or directly  witnessing the 
qualifying vitals, documentation of the verbal report will serve as the source documentation for determining 
eligibility.  Verbal reports will be documented  in the emergency medical record and will detail the information 
reported and by [CONTACT_20898].  
 
H.3. Intervention al Arm : The Intervention  will have both a prehospi[INVESTIGATOR_392165] -hospi[INVESTIGATOR_392166]. 
Investigational Drug Services (IDS) at the University of Pi[INVESTIGATOR_392167]. IDS at the University  of Pi[INVESTIGATOR_124565] a long track record of managing large multicenter trials and is 
currently executing and responsible for over 150 inpatient and outpatient clinical trials.  
H.3.1.  Prehospi[INVESTIGATOR_392168] : Once inclusion and exclusion are verified while the patient is 
being transported via emergency  medical transport to a STAAMP  trial participating center, in a 
randomized, double  blinded  fashion,  either 1 gram  bolus  of tranexamic acid diluted in 100cc of nor mal 
saline (pre -prepared  on emergency vehicle ) or placebo of identical  volume  will be infused intravenously 
or intraosseously  (if IO access was obtained due to a clinical need per standard of care)  into the patient 
over approximately 10 minutes  (“Bag A”) . After receiving the prehospi[INVESTIGATOR_392169], standard 
operating procedures utilizing goal directed crystalloid infusion will be followed (see H.7. Prehospi[INVESTIGATOR_392170] ) 
H.3.2. In-hospi[INVESTIGATOR_392171] : Upon arrival, patient blood and labs will be sampled and arrival 
rapid -TEG analysis will be performed within first 6 hours . After inclusion and exclusion criteria  
verification by [CONTACT_3647], in a double blinded, randomized fashion, those patients who r eceived 
tranexamic acid in the prehospi[INVESTIGATOR_392172] 1  of 3 different dosage regimens:  
 
1. Standard Tranexamic acid Dosing :  1 gram infusion over approximately 8 hours  
2. Repeat Tranexamic acid Dosing :  1 gram  bolus and 1 gram infusion over approximately 8 
hours  
3. Abbreviated Tranexamic acid Dosing : No further tranexamic acid to be given  
 
For intervention blinding purposes, each patient will receive both a bolus dose (either tranexamic acid or 
placebo) , “Bag B,”  and 8 h our infusion (either tranexamic acid or placebo) , “Bag C,”  depending on  the 
randomized  dosing regimen.  (Figure 13. below ) 
 
H.3.2.1 Adjustment For Renal Insufficiency : Subjects with a known or suspected history of 
renal insufficiency will receive a renal dose adjustment for the 8 hour repeat infusion  (Bag C) .  
The Estimated Body Weight Table will be used to determine the dose (Figure 12).  The dose will 
be capped at [ADDRESS_492570]  Dosing :        bolus - no dose adjustment / infusion - 1.25 mg/kg/hr x 8hrs  
2. Repeat Dosing :         bolus - no dose adjustment / infusion - 1.25 mg/kg/hr x 8hrs  
3. Abbreviated  Dosing :    bolus - no dose adjustment / infusion - 1.25 mg/kg/hr x 8hrs  
 
Renal adjustment will be based upon the most  current tranexamic acid Product 
Information /Package Insert  (Cyklokarpon package insert. West Ryde NSW: [COMPANY_007] Inc. 2010 
October ) where renal dosing adjustment is recommended for cardiac by[CONTACT_392322], 
whose eGFR is below 29 (< 29 mL/min/1.73m2).  
 
19 
  
 
 
 
 
Figure 12. Dose adjustment  
 
 
 
 
               Intervention         Phase  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Estimated Body Weight  Dose  
>100 kg  1000 mg (10 ml from vial)  
90-99.9 kg  900 mg (9 ml from vial)  
80-89.9 kg  800 mg (8 m1 from vial)  
70-79.9 kg  700 mg (7 ml from vial)  
60-69.9 kg  600 mg (6 ml from vial) 
50-59.9 kg  500 mg (5 ml from vial)  
40-49.9 kg  400 mg (4 ml from vial)  
30-39.9 kg  300 mg (3 ml from vial)  
20-29.9 kg  200 mg (2 ml from vial)  
[ADDRESS_492571]      Repeat    Abbreviated  
 
         Placebo Bolus                     TXA Bolus                     Placebo Bolus  
 
         TXA Infusion                   TXA Infusion                Placebo Infusion  
              (8hrs)     (8hrs)        (8hrs)  
In-Hospi[INVESTIGATOR_392173] 
(8hrs)  Received  
Prehospi[INVESTIGATOR_392174]-Hospi[INVESTIGATOR_392175] (10 min)  
Prehospi[INVESTIGATOR_392176], Labs, rapid -TEG 
Injury  
In-Hospi[INVESTIGATOR_392177]  
 
20 
  
 
 
 
 
 
H.4. Placebo/Control Arm : Prehospi[INVESTIGATOR_392178] 100cc of normal saline and infused over approximately 10 minutes. Patients who received prehospi[INVESTIGATOR_392179]-hospi[INVESTIGATOR_392180] d approximately 8 hour  placebo  infusion for 
blinding purposes.  
H.5. Randomization:  The randomization scheme will have both a prehospi[INVESTIGATOR_392165] -hospi[INVESTIGATOR_392166].  
H.5.1 . Prehospi[INVESTIGATOR_392181] : Individual patients meeting criteria while en route via 
emergency  medi cal transport will be randomized using an allocation sequence block size of 8 to either 1 
gram of tranexamic acid or placebo diluted in 100cc of normal saline given over approximately 10 
minutes. A single prehospi[INVESTIGATOR_392182] (1 -8) treatment 
packs (randomized with a computer random numb er generator ) will be distributed to each  respective 
helicopter  base (or station in the case of ground ambulance) . In an ascending numerical  order  fashion 
treatment packs will be utilized for enrolled  patients. The box and treatment pack # will be recorded  by 
[CONTACT_392323]. The patient  and all treatment and research staff  
will be  blinded to the treatment arm . All intervention vials will be covered to obscure view of vial 
contents to prehospi[INVESTIGATOR_392183] . IDS at the University of Pi[INVESTIGATOR_392184]. 
Additionally, the pharmacy at each respective participating  center will have access to the prehospi[INVESTIGATOR_392185] /assignment  scheme once the prehospi[INVESTIGATOR_392186] # are provided to 
them by [CONTACT_392324] .  
H.5.2. In-hospi[INVESTIGATOR_392187] : Using  a web based, ra ndomization  assignment  program  built 
specifically for the trial, research staff will provide and input the  prehospi[INVESTIGATOR_392188] # and 
treatment pack # into the web based platform at each site and be provided  the In-hospi[INVESTIGATOR_392189]. IDS at the University of Pi[INVESTIGATOR_392190] b e unblinded to the i n-hospi[INVESTIGATOR_392191].  The accepting research staff and pharmacy 
will verify they have the same in-hospi[INVESTIGATOR_392192].   An allocation se quence based upon a block size of 9 again generated with a  
computer random number generator will be utilized  for those who received prehospi[INVESTIGATOR_392193] .  Each respective IDS or pharmacy will prepare the inhospi[INVESTIGATOR_392194] ( approximate 10 
minute and 8 hour infusion). The patient and all treatment and research staff will be blinded to the 
treatment that is received . 
H.6. Blinding : The trial is a double blinded trial for both the prehospi[INVESTIGATOR_392165] -hospi[INVESTIGATOR_392195].  The participants, investigators, research coordinators and staff, and persons having any contact 
[CONTACT_392325]. The IDS at the University of Pi[INVESTIGATOR_392196]. Both IDS at the 
University of Pi[INVESTIGATOR_392197].  
H.7. Prehospi[INVESTIGATOR_392198] : To minimize over exuberant crystalloid resuscitation 
during the prehospi[INVESTIGATOR_392199], further crystalloid resuscitation  post-intervention  will 
follow a ‘goal directed ’ standard operating proc edure (SOP). Crystalloid infusion following the intervention 
will be based upon hemodynamic status (SBP < 90mmHg) with infusion of 500cc boluses  of crystalloid  for 
those patients with persistent  hypotension. Normotensive patients will receive crystalloid infusion at 
maintenance rate. (Figure 13. above) All crystalloid volumes will be monitored relative to transport time for all Figure [ADDRESS_492572] Operating Procedures : We have selected level I , academic, trauma centers with 
busy emergency  medical transport services that are recognized for providing high level care of the injured 
patient. As the intervention begins  in the pre -hospi[INVESTIGATOR_6885], there exists the potential for in -hospi[INVESTIGATOR_392200] -center study which does increase the study 
results applicability. However, to minimize those differences where high level evidence exis ts for the early in -
hospi[INVESTIGATOR_392201], and throughout a patients’ admission, SOPs for resuscitation and 
transfusion will be employed over the initial 24 hours and throughout a patients’ admission. SOPs for patients 
who are at risk of mass ive transfusion will target an FFP:PRBC ratio of at least 1:[ADDRESS_492573] transfusion 
practice evidence in the ICU will be followed including standar d restrictive transfusion guidelines for each 
respective institution in line with the TRICC trial recommendations (transfusion trigger of hgb - 7.0).89 
I. Outcome Variables/Definitions  
I.1. Primary Outcome : The primary outcome which will be utilized to power the study will be 30 day 
mortality . We anticipate that this study will be condu cted with an exception from consent for emergency 
research and will require FDA approval. We will power the study using 30 -day mortality as the primary 
outcome variable.   
I.2 Secondary Clinical Outcomes : Secondary clinical outcomes will include the  incidence of hyperfibrinolysis 
(EPL > 7.5% by [CONTACT_392316] -TEG analysis) upon arrival to the trauma bay within the first 6 hours , the incidence of 
acute trauma tic coagulopathy (INR > 1.4), 24 hour mortality, acute lung injury, multiple organ failure, the 
develop ment of nosocomial infection, early (24hr) seizures, in -hospi[INVESTIGATOR_392152], presenting base 
deficit, 24 hour crystalloid requirements and 6 hour and 24 hour blood and blood component transfusion 
requirements (PRBC, FFP and platelets). These same c linical outcomes will similarly be used for  the 
randomized  tranexamic acid dosage regimen comparison.  
I.3. Secondary Laboratory/ Mechanistic  Outcomes:  All laboratory /mechanistic  outcomes will be meas ured 
during the first 6 hours  from trauma center arrival and at 12 and 24 hours  (+/- 12 hours)  out from injury.  Those 
laboratory/mechanistic outcomes including flow cytometry which require fresh blood samples will be 
performed only at the University of Pi[INVESTIGATOR_392202] a subset of patient samp les unless participating centers have 
specific capabilities and following appropriate training  for standardization.  These same laboratory/mechanistic  
outcomes will similarly be used for  the randomized  tranexamic acid dosage regimen comparison at [ADDRESS_492574] -injury . 
I.4. Clinical O utcomes  Methods/ Definitions : All clinical outcomes will  be prospectively evaluated  for 
throughout ICU and hospi[INVESTIGATOR_392203]-
to-event statistical analysis.  
I.4.1 . 30 day  and 24 hour  mortality: [ADDRESS_492575] 24 hrs.  
I.4.2. Acute lung injury : Development of acute lung injury will be assessed utilizing the 1992 
American -European Consensus Conference definition90 which includes: 1) bilateral infiltrates on cxray, 
2) a capi[INVESTIGATOR_47469] < 18mmHg, and 3) Pao2/Fio2 ratio < 300 via blood gas analysis . In those 
patients without a Swan -Ganz catheter  (vast majori ty) to determine capi[INVESTIGATOR_47469], the 
absence of signs of or clinical concern for elevated left sided atrial pressures will be used for the 
diagnosis. All patients who remain intubated beyond the first [ADDRESS_492576] regression analysis.  
 I.4.3. Nosocomial  infection : Infectious outcomes of interest will include ventilator associated 
pneumonia, blood stream infection and urinary tract infections. S urgical site infections and post -
operative intra -abdominal collections will also be recorded but excluded as a principal secondary 
outcome event  to reduce the confounding effects of operative interventions which not all patients 
require. The development of  these nosocomial infections will be based upon positive culture evidence 
during hospi[INVESTIGATOR_063]. Infections will be monitored until post injury day 30 or ICU discharge. 
Diagnosis of ventilator  associated pneumonia requires a quantitative culture thresh old of ≥ 104 CFU/ml 
from broncho -alveolar lavage specimens in addition to standard x -ray and clinical criteria. Diagnosis of 
catheter -related blood stream infections requires  positive peripheral cultures with an identical organism 
obtained from either a positive semi -quantitative culture (>15 CFU/segment), or positive quantitative 
culture (>103 CFU/segment) from a catheter segment specimen. Urinary tract infections required > 105 
organisms/ml of urine. All time variables to the respective outcome  event will be determined from the 
day of initial injury, while the time to the first nosocomial infection will be used in those patients with 
multiple infections for time -to-event analysis and multivariate Cox proportional hazard regression 
analysis.  
I.4.4. Multiple organ failure : Organ dysfunction will be evaluated via a well -validated scoring system 
referred to as the Denver Postinjury Multiple Organ Failure Score.91-[ADDRESS_492577] scores of each of 
the individual systems over the course of the ICU stay.  A summary Denver score > 3  will b e classified 
as multiple organ failure (MOF). Scores will be determined daily up until post injury day [ADDRESS_492578]  regression analysis.  
I.4.5. Early seizures : Seizures will be prospectively monitored for over the first [ADDRESS_492579] -operatively or in those patients who did not require operative 
intervention will be documented. Neurology consultation will  be sought in those patients  with seizure 
activity. Classification of seizure type  and management  will be based upon  formal neurology 
consultation. Repeat occurrence and outcomes  associated with seizure will similarly be documented.  
I.4.6. In -hospi[INVESTIGATOR_392204] e mbolism : Pulmonary embolism that occurs during the primary 
admission hospi[INVESTIGATOR_392205]. Radiographic confirmation via CT 
imaging, transthoracic or trans -esophageal echo, or ventilation/perfusion scanning will be required.  
I.4.7 . Blood and blood component transfusion and resuscitation requirements : 6 and 24-hour 
transfusion requirements for blood, fresh frozen plasma and platelet  transfusion will be determined by 
[CONTACT_392326].  
Transfusion components which are initiated will be considered transfused irrespective of completion. 
Similar determi nations for crystalloid requirements  (volume in cc’s) over the first 24hrs of injury will 
occur.   
I.4.8. Adverse E vents : An adverse event (AE) is defined as any untoward medical occurrence in a trial 
subject undergoing a study procedure or administration o f a study drug. Thus, an AE is an unfavorable 
sign, symptom, or disease temporally associated with the study intervention, irrespective of whether it is 
considered related to the study intervention. A reportable AE is defined as an unexpected, serious even t 
related or possibly related to the study intervention or procedures.  
I.4.9. Unexpected Adverse Events : Unexpected adverse events will be defined as any serious 
unexpected adverse effect on health or safety or any unexpected life -threatening problem caused by, or 
associated with the interventions if that effect or problem was not previously identified in n ature, 
severity, or degree of incidence in the investigation plan or application (including a supplementary plan 
or application), or any other unexpected serious problem that relates to the rights, safety or welfare of 
subjects.  
23 
 I.4.10. Expected Adverse E vents:  Expected adverse events are commonly observed in patients who are 
at risk of hemorrhage following traumatic injury and may or may not be attributable to the tranexamic 
acid intervention. These will be monitored and reported throughout the time period for the trial. Clinical 
diagnoses of pneumonia, sepsis, cerebral bleeding, stroke, seizures, surgical interventions, complications 
due to specific injuries as well as other major medical or surgical complications are commonly observed 
in these patients. They w ill be recorded as noted in the hospi[INVESTIGATOR_44458].  
I.5. Laboratory/Mechanistic Outcome Methods /Definitions : All measurements will be performed within [ADDRESS_492580] injury  (+/- 12 hours)  for the randomized dosage regimen 
comparison . One more additional blood sample will be collected at 72 hours (± 12 hrs)  for D-dimer, activated 
Protein C levels and plasmin -antiplasmin complexes  measurements. Excluding r -TEG analysis and PT/ INR 
measurements, all bl ood and serum samples will be spun, stored and batched at their respective institution and 
delivered to the Univers ity of Pi[INVESTIGATOR_392206] . 
Those laboratory/mechanistic outcomes including flow cytometry which require fresh blood samples will be 
performed only at the University of Pi[INVESTIGATOR_392207] a subset of patient samples  unless participating centers have 
specific capabilities and following appropriate training for standardization.  
I.5.1. Coagulo pathy and T EG parameters  (Aim#2 ): To appropriately characterize differences in 
coagulopathy between tranexamic acid and placebo, i n addition to r -TEG measurements of 
hyperfibrinolysis, presenting PT/ INR and additional TEG parameters will also be measured ( ACT, r -
value, k -time, α -angle, maximal amplitude, and G -values  ). All rapid TEG measurements will be 
performed within 6 hours  of arrival  and at 12 and 24 (+/- 12 hours) hours post injury. TEG analysi s will 
be performed on a TEG® 5000 Thromb oelastograph® Hemostasis Analyzer which will reside  within the 
emergency department of each participating site . Standard laboratory INR will be drawn and measured  
at each institution within 6 hours  of arrival  and at 12 and 24 hours  (+/- 12 hours) . To further quantify the 
coagulopathy and hyperfibrino lysis post injury in these patients, D-dimer, activated Protein C levels and 
plasmin -antiplasmin complexes  will be measured by [CONTACT_392327] . (ANIARA , USCN  Life Science 
Inc., DRG International, Inc.)  Plasmin -antiplasmin complexes may represent a  more common, 
subclinical measurement of fibrinolytic activity  that is not able to be assessed using standard TEG  
analysis, but elevated levels are associated with significantly worse outcome post injury  and may be a 
marker than demonstrates the mechanism by [CONTACT_392328] . 
I.5.2. Exploratory Inflam matory Response Outcomes  (Aim #3): Plasmin has pro -inflammatory 
effects by [CONTACT_392329], neutrophils, platelets, endothelial and dendritic cells and induces pro -
inflammatory genes.51,[ADDRESS_492581] demonstrated the ability of plasmin to stimulate the production reactive oxygen 
species and promote the release of lipid mediators and cyt okines via complement activation.51,53 To 
appropriately characterize the potential non -antifibrinolytic mechanisms responsible for the mortality 
benefit attributable to tranexamic acid,  serum plasmin levels, and plasmin mediated compliment 
activation (C3a and Factor B) and HMGB1 levels will be measured by [CONTACT_392330]  (MyBioSource, BD Biosciences) . A Cytokine 10 -plex Panel for the Luminex® 
platform will be utilized for all early inflammatory cytokine  measurements . (Novex®)  These same 
inflammatory re sponse measurements will be utilized for the randomized dose regimen comparison at 
[ADDRESS_492582] injury.  
I.5.3 . Plate let, Leukocyte and Inflammatory Gene Expression Measurements (Aim#3) : To further 
characterize an anti -inflammatory effect of tranexamic acid mediated thru reduced plasmin activation, 
for those patients enrolled at the University of Pi[INVESTIGATOR_9109],  whole  fresh  blood will be obtained and  
platelet and leukocyte activation will be meas ured on a subset of patient samples  using flow cytometry 
(FACS) analysis utilizing platelet activation specific antibodies (CD41 and CD62P , Molecular Probes® ) 
and Leukocyte activation specific antibodies (CD11a and CD35 , Molecular Probes® ). Inflammatory 
gene expression will be assessed via RT -PCR with a focus  on evidence based gene targets including 
those  identified as being most dramatically perturbed following  severe injury from the Glue Grant  study 
cohort including CD177, MMP8, lactotransferrin, haptoglobin, S100A8  (calgranulin), MYBL1  
24 
 (myeloblastosis viral homologue, v -myb), KLRF1  (Killer cell lectin like receptor subfamily F, member 
1), TGFBR3  (TGF -β receptor III subunit ), and TCRA  (T cell receptor α subunit ).94 These studies  will be 
performed at a University of Pi[INVESTIGATOR_392208] -PCR core facilities  which will be available 24 
hours/day  over the three years of the study .  
 
J. Anal ysis Plan :  
The over arching goal of the study proposal is to  assess the efficacy  of prehospi[INVESTIGATOR_392209].  
Additional goal s include dose regimen comparison and characterization of the mechanisms responsible for 
tranexamic acid’s beneficial effects.  All primary and secondary analyse s will be performed based on  the Intent -
to-Treat principle for the prehospi[INVESTIGATOR_392210] . 
J.1. Data Analys is for Primary Outcome : We follow an intent -to-treat approach in analyzing our primary 
outcome of 30 day  mortality.  
J.1.1 . Primary Primary  Outcome  (30 Day Mortality) : All randomized subjects will be included in the 
analysis to test the differences in [ADDRESS_492583] is deceased at 30 
days is d escribed in detail in section ( N.6.). If more than 15 % of the subjects are missing the 30 day outcome, 
we will consider this outcome as descriptive only. We will analyze this endpoint as  a fixed point in time using a 
two-sided Mantel -Haenszel (M -H) test ta king site, the stratifying variable (strata), into account.  The M -H test is 
robust to lack of homogeneity of odds ratio although power would be reduced. This  approach has more power 
than the survival analysis described below given the potential for crossin g hazard functions. We will also test 
homogeneity of the odds ratios across sites using the Breslow -Day test. We will compute 95% confidence 
intervals on mortality by [CONTACT_105840] [ADDRESS_492584] of imputation ‘as alive ’ on the treatment group comparisons and confidence limits 
for the [ADDRESS_492585] for and take 
crossing hazards into account if applicable. As an additional exploratory analysis we will compare 30 -day 
survival in the two groups adjusting for the covariates listed above and any additional baseline covariates that 
are imbalanced bet ween treatment groups (p<0.10) using the same screening approach to decrease the number 
of covariates included in the model, if necessary.  
J.2. Analysis of  Prehospi[INVESTIGATOR_392211] : Unless there is sufficient power 
(predetermined before th e analysis is begun), the approach to analysis of secondary endpoints will generally be 
calculation of confidence limits on intervention group differences or model parameters rather than formal tests 
of significance at a specified critical level as the tri al will not have sufficient power to detect difference in all of 
these outcomes. However, these comparisons will add to the knowledge of the benefits and risks of the 
interventions. Parametric and nonparametric comparisons will be applied according to norm alcy. All tests used 
will be two -tailed tests at significance level (alpha) of  0.05.  For prehospi[INVESTIGATOR_392212] -square with 95% confidence intervals for dichotomous outcomes and parametric or non -parametric 
testing for con tinuous variable with 95% confidence intervals. For prehospi[INVESTIGATOR_392213] -parametric testing for continuous variable with 95% 
confidence intervals.  
25 
 J.3. Analysis for Second Stage In -hospi[INVESTIGATOR_392095] : Chi -square test will be able to 
test the effect of different tranexamic dosage regimens on hyperfibrinolysis.  Similarly, chi -square will be used 
to detect any differences between dosage groups for [ADDRESS_492586] of dosage on hyperfibrinolysis. Similarly  Cox 
proportional hazards regression can be used for 30 day mortality. For In -hospi[INVESTIGATOR_392214] -square with 95% confidence intervals for dichotomous 
outcomes and parametric or non -parametric  testing for continuous variable with 95% confidence intervals. For 
In-hospi[INVESTIGATOR_392215] -parametric testing for continuous variable with 95% confidence interva ls. 
J.4. Predefined Subgroup Analyses : Predefined subset analyses will be performed looking at 1.) patients who 
ultimately did or did not required blood transfusion  2.) those patients with significant traumatic brain injury 
(Head AIS >2) versus those witho ut signific ant brain injury (Head AIS ≤ 2), 3 .) those patients enrolled from the 
scene of injury versus those enr olled from a referral hospi[INVESTIGATOR_307], 4 .) those patients that require operative 
intervention in the first 24 hours, 5.) those patients with a preinjury history of vitamin K antagonist medication 
history vers us those without,  6 .) those patients with preinjury history of antiplatelet medication his tory. 7.) 
those  patients who ultimately did or did not require massive transfusion (≥ [ADDRESS_492587] 24hrs).   It is 
recognized that the study is not appropriately powered for these subgroup comparisons and the results and 
conclusions formulated fr om these subgroup analyses will be considered exploratory in nature and will not be 
used as a basis for treatment recommendations.  
J.5. Randomization of Ineligible S ubjects:  It is anticipated that there will be a small proportion of 
patients enrolled who r eceive either tranexamic acid or placebo that in retrospect will not have met the 
entry crit eria and are thus ineligible. In this circumstance, patients will be analyzed according to the 
group to which they were randomized. Subgroup analyses based on eligi bility criteria will be performed 
if the number of patients so affected is large. However, based on the relatively limited inclusion and 
exclusion criteria it is anticipated that the frequency of this event will be low.    
J.6. Non-adherence : In some circumstances, patients may receive the incorrect treatment packet . Non -
adherence is most likely to occur in the case of the exsanguinating patient when time is limited and the 
wrong treatment pack is utilized. Fortunately, this event is relative ly rare. In keepi[INVESTIGATOR_392216] -
to-treat analytic design, these patients will be analyzed with the group to which they were  to be  
randomized  to. 
J.7. Missing Data : For 30 -day mortality, given the transient nature of many of the subjects, extensive e fforts 
will be made to ascertain vital status ( see N.6.). Batch searches of the mortality databases will continue every 
quarter for subjects with unknown status, until trial closeout. For interim and final analyses, subjects who have 
not been reported as d eceased by [CONTACT_4475] 30 following ED admission from any of these sources we will use 
multiple imputation for the final value. As sensitivity analyses we will report the data with and without 
imputation. We will also report an analysis consistent with that used i n other studies counting those missing as 
alive on day 30.  
 
K. Samp le Size Justification and Power Analysis:   
We have determined the sample size for this proposal and powered the analysis  based upon the  primary 
outcome , 30 day mortality . 
K.1. Primary Outcome  30 day mortality : Assuming  a baseline mortality risk of 16% as was demonstrated in 
the Crash -[ADDRESS_492588] a 90% power to detect a 7% or greater difference in [ADDRESS_492589] 80% powe r to detect a 6% or greater difference in [ADDRESS_492590] emergency  medical programs were screened using the 
proposed inclusion criteria over 2012 data and selected for participation based upon this information, this 
sample size estima te is appropriate and attainable.  
 
 Sample  Sample  Prop|H1  Prop       
 Size Size Grp 1 or  Grp 2 or  Diff Diff    
 Grp 1  Grp 2  Trtmnt  Control  if H0  if H1  Target  Actual   
Power  N1 N2 P1 P2 D0 D1 Alpha  Alpha  Beta 
0.9000  497 497 0.0919  0.1600  0.0000  -0.0681  0.0500   0.1000  
0.8500  497 497 0.0965  0.1600  0.0000  -0.0635  0.0500   0.1500  
0.8000  497 497 0.1003  0.1600  0.0000  -0.0597  0.0500   0.2000  
 
L. Human Subjects:  
We anticipate that this study would be conducted with an exception from consent for emergency research , 
including community consultation, public notification, as well as notification of patients or their legally -
authorized representative as soon as feasible after enrollment. The latter shall include provision of an 
opportunity to opt out from ongoing parti cipation that will be given through oral and written communication.  
 
Community consultation as outlined by [CONTACT_392331]. Since the 
population eligible for enrollment includes all citizens in the study regions it wi ll not be possible to target any 
particular small group. Feedback from the community will be obtained by [CONTACT_392332]. If requested, bracelets will be made available that could be 
worn b y members of the community who do not want to participate. Public notification and community 
consultation will be performed as directed by [CONTACT_392333], targeted small group meetings or consultation 
with community leaders. Due to ongoing participation in large multicen ter research organizations, our 
institution and participating centers have significant experience with community consultation and  notification 
practices.  
 
Benefits of participation in the STAAMP  trial for both interventional and control  subjects:  
A unique benefit regarding participation in the STAAMP  trial is that all research results for both Tranexamic 
acid and control arms of the study may be used to further inform clinical care decisions throughout a 
participants hospi[INVESTIGATOR_4408].  Participation in the trial may also aid in early recognition of traum a induced 
coagulopathy due to the early measurements of INR and thrombelastography (TEG) which will be performed 
on all enrolled subjects. TEG is an FDA approved tool, however, currently it is not standard of care and on ly a 
small proportion of trauma centers across the country routinely obtain early INR and point of care rapid -TEG 
analysis in the emergency department, soon after arrival in patients in hemorrhagic shock.  Early recognition of 
coagulopathy for all enrolled subjects may lead to earlier interv ention and in hospi[INVESTIGATOR_392217].     
 
M. Screening , Enrollment  and Notification :  
The Department of Surgery at the University of Pi[INVESTIGATOR_392218] (MACRO). MACRO is a unique, 
[ADDRESS_492591] center model and provides  ‘cost -neutral’  services to 
clinical investigators from diverse specialties in order to conduct clinical and translational research. The 
University of Pi[INVESTIGATOR_392219] . MACRO research 
coordinators and par ticipating site research coordinator s will document and verify  all trauma a rrivals  via 
emergency  medical transport  for enrollment . Those patients who met  inclusion and exclusion criteri a en route 
via emergency  medical transport that were enrolled will be  verified and enrolled patients will  undergo initial 
laboratory and blood sampling  and will have  point of care rapid thromboelastography (TEG) performed for 
coagulation parameter measurements within [ADDRESS_492592]’s legally authorized representative as soon as feasible for 
notification of enrollment and will provide an opportunity to opt out from  ongoing participation. Summary of 
these efforts will be documented in the patient’s chart. If the subject becomes competent during the study period 
then he/she will be approached by [CONTACT_392334] a similar provision  of 
an opportunity to opt out from ongoing participation.  
 
We will inform the family member or LAR at the earliest feasible opportunity of the subject’s inclusion in the 
clinical trial, the details of the trial, other information contained in the informed consent document, and that he 
or she may discontinue the subject’s participation at any time without penalty or loss of benefits to which the 
subject is otherwise entitled. The therapeutic window for this trial is zero due to prehospi[INVESTIGATOR_392220]. 
Such notification is not usually feasible before or at the actual time of treatment or trial enrollment and must be 
deferred until after resuscitation efforts have been completed. Such notification will be in person wherever 
possible and as soon as fea sible (unless otherwise directed by a local IRB). A log will be kept to document the 
attempts made to contact [CONTACT_55639]/family member. The log will be included in the paper data collection forms.  
 
The investigators will utilize social workers and law enforce ment personnel to try to locate the patient's legally 
authorized representative. If that search is unsuccessful, a notification letter will be sent to the subject's 
authorized representative explaining the study and providing contact [CONTACT_392335]. The 
letter will be sent via registered mail or by [CONTACT_392336]. 
N. Data   
N.1. Sources : Data will be collected prospectively as patient care progresses. This will include a review of the 
emergency  medical  patient care report(s), E mergency Department and  electronic/  paper  hospi[INVESTIGATOR_1097].  
N.2. Prehospi[INVESTIGATOR_392221] : Demographics , emergency  medical response times (call receipt to 
arrival, arrival at patient side,) i njury characteristics, vital signs, prehospi[INVESTIGATOR_392222], 
(plasma volume, crystalloid volume, blood transfusion volume, starting at referring hospi [INVESTIGATOR_392223] ) 
prehospi[INVESTIGATOR_355062] (needle decompression, chest tubes) referring hospi[INVESTIGATOR_392224], and interventions.  
N.3. In-Hospi[INVESTIGATOR_392225] : Demogra phics, shock severity (base defi cit, lactate), injury 
characteristics, ED vitals, ED interventions (chest tubes, intubation) ,  operative interventions  and timing of 
interventions , injury severity score, ICU days, ventilator days, length of stay, multiple organ dysfunction scores 
(daily), nos ocomial infectious outcomes, blood gas  results, cxray reads, transfusion of blood and blood 
components, resuscitation requirements , all primary and secondary outcomes . 
28 
 N.4. Data Entry : MACRO and associated internet technology affiliates at the University of Pi[INVESTIGATOR_392226] -based data entry platform  to collect necessary information from all participating sites  which will 
also be utilized for randomization assignment . Web entry forms will have dynamic features such as immediate 
checks on data and relationships within a form and between forms. Details and clarification about data items 
will be provided using pop -up windows and links to appropriate sections of the on -line version o f the Manual of 
Operations. Data encryption and authentication methods will be used. Additional features will be built into the 
web entry forms including: forms transmission  history, access to past forms, tracking of data corrections, and 
the capability to  save and re -load incomplete forms.  
N.5. Database Management : A two -tiered database structure will be created. A front -end database will serve 
the web entry needs, using a database management system well -suited to handling updates from multiple 
interactive  users. The data from this database will be transferred periodically (e.g. weekly) to a data repository 
that can be used by [CONTACT_108250]. These data sets will be the basis for data queries, analyses and 
monitoring reports. Various versions  of this database will be kept as needed, e.g. for quarterly performance 
reports. Backup of data and programs will be performed at frequent intervals. Access to data will be limited to 
those who need access to perform their tasks. The database management s ystem is able to manage large 
quantities of data, to merge data from multiple databases as required, to handle complex and possibly changing 
relationships, and to produce analysis datasets that can be imported into a variety of statistical packages.  
N.6. Mortality Outcome Data (30 day) : If discharge occurs before hospi[INVESTIGATOR_19156] [ADDRESS_492593]’s vital status. If the subje ct is discharged to his/her usual residence before day 30, the 
research staff will contact [CONTACT_392337]/legally authorized representative (LAR). If vital status 
remains unknown the clinical site will request periodic searches for the subject’s social security number in the 
Social Security Master Death Index, the respective State Health Department’s vital statistics/mortality database, 
and the mortality databases of a credit reporting agency, e.g., Experian. For subjects not reported as  deceased by 
[CONTACT_392338] 30 following ED admission, batch searches of the mortality databases will continue every 
quarter until trial close -out. Date (and cause of death when available) for out -of-hospi[INVESTIGATOR_392227]; however, under lying and contributing causes of death may not be available from these sources. 
Clinical sites will follow local and state HIPPA guidelines for release of PHI for research.  
 
O. Training  and Participating Site Coordination :  
As the coordinating center for t he proposed trial, the University of Pi[INVESTIGATOR_392228], prehospi[INVESTIGATOR_392229], sample and data collection, and maintenance of  data 
integrity . Research coordinators , prehospi[INVESTIGATOR_392230], specific  inclusion and exclusion criteria, 
sample collection and processing, prehospi[INVESTIGATOR_392231], and rapid t hromboelastography (TEG) 
performance . Training verification and retraining will occur at yearly  interval s or more commonly if  new staff 
is hired at individual participating sites. Trial enrollment and maintenance of data integrity will be assessed 
monthly  using the web based data platform. Trial screening, enrollment and d ata completeness and accuracy 
will be accessed at [ADDRESS_492594]  (DSMB) : Data safety and monitoring over the course of the clinical trial 
will fall under the responsibility of an independent data sa fety and monitoring board .  The DSMB will consist 
of at a minimum, a hematologist with expertise in transfusion medicine, a trauma /critical care surgeon, an 
epi[INVESTIGATOR_392232], and a biostatistician all of whom will have no proprietary 
interest in the outcome of the trial.  The responsibilities of the DSMB will fall under several domains.  Prior to 
beginning the accrual of subjects, the DSMB will review the research protocol and identify logistic problems 
that may pose problems with randomization schemes and distribution of Tranexamic acid .  At this early phase, 
[ADDRESS_492595] 
of the trial is unnecessary due to strong evidence of benefit or futility.   
     Although the DSMB will make t he final decision about the interim monitoring plan, we anticipate that the 
DSMB will evaluate the rate of adverse events between the treatment and control arms at 6 months and then 
annually during enrollment. The DSMB will also monitor primary, secondary study outcomes between the 
treatment and control groups including main effects and a priori subgroups as specified elsewhere in the 
protocol. The DSMB will advise the investigators if a change in the protocol is warranted based on this interim 
monitoring.  
P.2.  Research Monitor  
 The Research Monitor is responsible to oversee the safety of the research subjects and report 
observations/findings to the IRB or a designated institutional official. The Research Monitor will review all 
unanticipated problems involving risks to subjects or others associated with the protocol and provide an 
independent report of the event. The Research Monitor may discuss the research protocol with the investigators; 
shall have authority to stop a research protocol in p rogress, remove individual human subjects from a research 
protocol, and take whatever steps are necessary to protect the safety and well -being of human subjects until the 
IRB can assess the monitor's report; and shall have the responsibility to promptly re port their observations and 
findings to the IRB or other designated official and the HRPO.  
P.3. Assessing and Reporting Adverse Events (AEs) : All Adverse Events will be documented and assessed 
for relationship to the study intervention. Reporting forms wil l be submitted to the DSMB and IRB. All 
potential adverse events will be reviewed as to treatment arm and further classified by: a) Severity (life -
threatening, serious, non -serious); and b) Expected vs. Unexpected. For serious adverse events, the coordinat ing 
center will notify the DSMB as well as appropriate regulatory agencies, site, and sponsor promptly. The 
coordinating center will tabulate and report compliance, data quality, and non -serious adverse events on a 
regular basis. Life -threatening or fatal unexpected AE associated with the study intervention or procedure 
should be reported within [ADDRESS_492596] be 
reported to the DSMB and IRB within 5 working days with follow up submission of a detailed written report. 
The DSMB will determine if the event merits an immediate review.  
A summary report of the DSMB’s findings will be submitte d to regulatory agencies. At least one specialized 
clinician from the Data Safety Monitoring committee will be responsible for monitoring data safety. All related 
unanticipated problems will be directly handled by [CONTACT_3449]’s PIs and reported accordingly. We w ill also follow 
Department Of Defense Unique requirements documentation. The University of Pi[INVESTIGATOR_392233], analysis, and reporting of adv erse effects using a standardized report form.  The coordinating center 
will be responsible for all oversight of these risk assessments with monthly evaluations.  
P.4. Interim Analyses : In concert with the DSMB, prior to initiation of the trial, the final mo nitoring plan will 
be developed to serve as the guide to the DSMB’s decision -making process concerning early stoppi[INVESTIGATOR_392234]. We will recommend interim ana lyses as 1/3 and 2/3 of patient  enrollment. In making the decision to 
recommend termination of the study, the DSMB shall be guided by [CONTACT_392339]: (i) a formal 
stoppi[INVESTIGATOR_392235] (comparison of treatment groups on the in -hospi[INVESTIGATOR_16813] 24 
hour blood transfusion requirements), (ii) info rmation on safety outcomes by [CONTACT_1570], (iii) consistency 
between results for primary and secondary outcomes, and (iv) consistency of treatment effects across 
subgroups. Formal interim analyses will be performed at 6 months and then annually through out enrollment  
. The DSMB will use the results of implementing the stoppi[INVESTIGATOR_392236] a guideline in evaluating the evidence for 
treatment effects. In making a recommendation to terminate the study, the DSMB will also consider information 
on safety outcomes,  as well as consistency of outcomes for secondary outcomes and consistency of outcomes 
within important subgroups as described previously. The group sequential method described by O’Brien and 
[ADDRESS_492597] of repeated testing on the probability of a 
Type I error.95 
 
Based on our power analysis, sample sizes of 497 in interventional group and 497 in control group can achieve  
80% power to detect a difference of 0.06 between the group proportions of 0.10 and 0.16 at a significance level  
(alpha) of 0.[ADDRESS_492598] based our testing on group sequential design that  
dividing patient entry into a fixed number of equal -sized groups and provides ethical and practical ways to make 
decision to stop the trial or continue based on repeated significance tests of the accumulated data after each group  
 is evaluated.  
 
According to the above power calculation and following the group sequential method described by O’Brien and 
Fleming in developi[INVESTIGATOR_392237] a Type I error, 
we will have equally spaced looks at 33%, 67% and 100% of patient accruals. This is equal to 166, 332, and 
[ADDRESS_492599] boundaries according to O’Brien -Fleming method.    
 
Details when Spending = O'Brien -Fleming, N1 = 497, N2 =497, P1 = 0.10, P2 = 0.16  
  Lower  Upper  Nominal  Inc Total  Inc Total 
Look  Time  Bndry  Bndry  Alpha  Alpha  Alpha  Power  Power  
1 0.33 -3.[ZIP_CODE]  3.[ZIP_CODE]  0.000207  0.000207  0.000207  0.018687  0.018687   
2 0.67 -2.[ZIP_CODE]  2.[ZIP_CODE]  0.012025  0.011890  0.012097  0.399207  0.417894   
3 1.00 -1.[ZIP_CODE]  1.[ZIP_CODE]  0.046259  0.037903  0.050000  0.382494  0.800388   
Drift 2.[ZIP_CODE]  
 
 
Look: These are the sequence numbers of the interim tests.  
 
Time: These are the time points at which the interim tests are conducted. This is also related to proportion of subject accruals  
 
Lowe r and Upper Boundary: These are the test boundaries. If the computed value of the test statistic z is between these values, the trial should 
continue. Otherwise, the trial can be stopped.  
 
Nominal Alpha:  This is the value of alpha for these boundaries if they were used for a single, standalone test. Hence, this is the significance level 
that must be found for this look in a standard statistical package that does not adjust for multiple looks.  
 
Inc Alpha: This is the amount of alpha that is spent by [CONTACT_392340]. It is close to, but not equal to, the value of alpha that would be achieved if 
only a single test was conducted. The difference is due to the correction that must be made for multiple tests.  
 
Total Alpha: This is the total amount of alpha that is used up to and including the current test.  
 
Inc Power: These are the amounts that are added to the total power at each interim test. They are often called the exit probabilities be cause they give 
the probability that significance is found and the trial is stopped, given the alternative hypothesis.  
 
O’Brien -Fleming boundary values are inversely proportional to the square root of information levels on the standardized  Z scale 
(O’Brien and Fleming 1979).  The O’Brien -Fleming boundary is conservative in the early stages and tends to stop the trials early only 
with a small  P-value. But the nominal value at the final stage is close to the overall  P-value of the design.  
 
[ADDRESS_492600] boundary (1.96 and -1.96) at the last look.  
 
 
Interim Analysis References  
1. Chow, S.C.; Shao, J.; Wang, H. 2003. Sample Size Calculations in Clinical Research. Marcel Dekker. [LOCATION_001].  
2. Lan, K.K.G. and DeMets, D.L. 1983. 'Discrete sequential boundaries for clinical trials.' Biometrika, 70, pages 659 -663. 
3. O'Brien, P.C. and Fleming, T.R. 1979. 'A multiple  testing procedure for clinical trials.' Biometrics, 35, pages 549 -556 
4. Pocock, S.J. 1977. 'Group sequential methods in the design and analysis of clinical trials.' Biometrika, 64, pages 191 -199 
5. Reboussin, D.M., DeMets, D.L., Kim, K, and Lan, K.K.G. 1992. ' Programs for computing group sequential boundaries using 
the Lan -DeMets Method.' Technical Report 60, Department of Biostatistics, University of Wisconsin -Madison.  
 
P.5 IP Stoppi[INVESTIGATOR_1869] :  Study product administration should  not be stopped except for in th e rare instance that 
necessary treatment or clinical condition would be contraindicated to TXA administration , patient has a confirmed (as 
determined by [CONTACT_80604]) seizure during administration, or if the patient is experiencing a suspected 
allergic reaction to the study product . 
Q. Quality Control and Assurance  
Q.1. Protocol Compliance  and Reporting : The PI [INVESTIGATOR_392238]. 
In that event, the PI [INVESTIGATOR_392239]. The PI [INVESTIGATOR_392240], safety information and other changes. Persistent or seriou s 
noncompliance may result in termination of the study.  The PI [INVESTIGATOR_392241] . If changes to the design of the 
study are made by [CONTACT_978], a pro tocol amendment must be submitted to the University of Pi[INVESTIGATOR_68348]. 
Changes in the protocol cannot be instituted until appropriate approval has been given by [CONTACT_1201].  
Q.2. Investigator Responsibilities : The PI [INVESTIGATOR_392242] 9 (Commitments) of FDA form 1572, Title 21 of the 
US CFR, and the ICH GCP Guidelines (E6, Section 5) as well as all national, state and local laws of applicable 
O'Brien-Fleming Boundaries with Alpha = 0.[ADDRESS_492601] their origin 
in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable requirements.  
 
R. Study Limitations:  
The study is a multi -center trial with the potential for variation in prehospi[INVESTIGATOR_392243] -hospi[INVESTIGATOR_392244] -injury care potentially affecting  the primary and secondary outcomes for the proposal. We 
elected to standardize prehospi[INVESTIGATOR_392245] . 
Importantly , we selected similar academic, level 1, participating centers based upon their patient and emergency  
medical transport volumes, the re prior experience with clinical research and prior participation in prior multi -
center trials,  and who practice up -to-date evidence based trauma care,  in attempts  to minimize significant 
variation in post injury care.  
Bibliography  
 
1. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epi[INVESTIGATOR_623], 
clinical presentations, and therapeutic considerations. J Trauma. Jun 2006;60([ADDRESS_492602]):S3 -11. 
2. Hoyt DB. A clinical review of bleeding dilemmas in trauma.  Semin Hematol. Jan 2004;41([ADDRESS_492603] 1):40 -43. 
3. Holcomb JB. Methods for improved hemorrhage control. Crit Care. 2004;[ADDRESS_492604] 2:S57 -60. 
4. Shackford SR, Mackersie RC, Holbrook TL, et al. The epi[INVESTIGATOR_355070]. A population -based 
analysis. Arch Surg. May 1993;128(5):571 -575.  
5. Gentilello LM, Pi[INVESTIGATOR_355069]. Trauma critical care. Am J Respir Crit Care Med. Mar 2001;163(3 Pt 1):604 -607. 
6. Wilson RF, Dulchavsky SA, Soullier G, Beckman B. Problems with 20 or more blood transfusions in 24 hours. 
Am Surg. Jul 1987;53(7):410 -417.  
7. Ferrara A, MacArthur JD, Wright HK, Modlin IM, McMillen MA. Hypothermia and acidosis worsen 
coagulopathy in the patient requiring massive transfusion. Am J Surg. Nov 1990;160(5):515 -518.  
8. Moore EE. Thomas G. Orr Memorial Lecture. Staged laparotomy for the hypothermia, acidosis, and 
coagulopathy syndrome. Am J Surg. Nov 1996;172(5):[ADDRESS_492605] B. Predicting life -threatening 
coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma. May 
1997;42(5):857 -861; discussion 861 -852.  
10. Patt A, McCroskey BL, Moore EE. Hypothermia -induced coagulopathies in trauma. Surg Clin North Am. Aug 
1988;68(4):[ADDRESS_492606] WB. Acidosis -induced coagulopathy. Surg Forum. 1979;30:471 -473.  
12. Shaz BH, Winkler AM, James AB, Hillyer CD, Macleod JB. Pathophysiology of Early Trauma -Induced 
Coagulopathy: Emerging Evidence for Hemodilution and Coagulation Factor Depletion. J Trauma. Mar 31 
2011.  
13. Curry N, Hopewell S, Doree C, Hyde C, Brohi K, Stanworth S. The acute management of trauma hem orrhage: a 
systematic review of randomized controlled trials. Crit Care. Mar 9 2011;15(2):R92.  
14. Curry N, Stanworth S, Hopewell S, Doree C, Brohi K, Hyde C. Trauma -Induced Coagulopathy -A Review of the 
Systematic Reviews: Is There Sufficient Evidence to G uide Clinical Transfusion Practice? Transfus Med Rev. 
Mar 3 2011.  
15. MacLeod J, Lynn M, McKenney MG, Jeroukhimov I, Cohn SM. Predictors of mortality in trauma patients. Am 
Surg. Sep 2004;70(9):805 -810.  
16. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J 
Trauma. Jul 2003;55(1):39 -44. 
17. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. Jun 2003;54(6):1127 -1130.  
18. Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in multiple injury: an analysis from the German 
Trauma Registry on 8724 patients. Injury. Mar 2007;38(3):298 -304.  
33 
 19. Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of 
trauma in combat casualties. J Trauma. Jun 2008;64(6):1459 -1463; discussion 1463 -1455.  
20. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pi[INVESTIGATOR_169917]. Acute traumatic coagulopathy: initiated 
by [CONTACT_392341]: modulated thro ugh the protein C pathway? Ann Surg. May 2007;245(5):[ADDRESS_492607] of hypothermia on dilutional coagulopathy. J 
Trauma. Jun 1994;36(6):847 -851.  
22. MacLeod JB. Trauma and coagulopathy: a new para digm to consider. Arch Surg. Aug 2008;143(8):797 -801.  
23. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr 
Opin Crit Care. Dec 2007;13(6):680 -685.  
24. Nascimento B, Callum J, Rubenfeld G, Neto JB, Li n Y, Rizoli S. Clinical review: Fresh frozen plasma in massive 
bleedings - more questions than answers. Crit Care. 2010;14(1):202.  
25. Frith D, Brohi K. The pathophysiology of trauma -induced coagulopathy. Curr Opin Crit Care. Dec 
2012;18(6):631 -636.  
26. Frith D, Davenport R, Brohi K. Acute traumatic coagulopathy. Curr Opin Anaesthesiol. Apr 2012;25(2):229 -234.  
27. Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma. Oct 
2008;65(4):748 -754.  
28. Kutcher ME, Cripps MW, McCreery RC, et al. Criteria for empi[INVESTIGATOR_392246]. J 
Trauma Acute Care Surg. Jul 2012;73(1):87 -93. 
29. Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute 
coagulopat hy of trauma. Ann Surg. Sep 2010;252(3):434 -442; discussion [ADDRESS_492608] 2012;215(4):496 -502.  
31. Cotton BA, Harvin JA, Kostousouv V, et al. Hyperfibrinolysis at admission is an uncommon but highly lethal 
event associated with shock and prehospi[INVESTIGATOR_392247]. J Trauma Acute Care Surg. Aug 
2012;73(2):365 -370; discussion 370.  
32. Raza I, Daven port R, Rourke C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. 
J Thromb Haemost. Nov 23 2012.  
33. Kashuk JL, Moore EE, Sawyer M, et al. Postinjury coagulopathy management: goal directed resuscitation via 
POC thrombelast ography. Ann Surg. Apr 2010;251(4):[ADDRESS_492609], Rossaint R. Coagulopathy and blood component transfusion in trauma. Br J Anaesth. Aug 
2005;95(2):130 -139.  
35. Lucas CE, Ledgerwood AM. Clinical significance of altered coagulation tests after massiv e transfusion for 
trauma. Am Surg. Mar 1981;47(3):125 -130.  
36. Murray D, Pennell B, Olson J. Variability of prothrombin time and activated partial thromboplastin time in the 
diagnosis of increased surgical bleeding. Transfusion. Jan 1999;39(1):56 -62. 
37. Kashuk JL, Moore EE, Le T, et al. Noncitrated whole blood is opt imal for evaluation of postinjury coagulopathy 
with point -of-care rapid thrombelastography. J Surg Res. Sep 2009;156(1):133 -138.  
38. Carroll RC, Craft RM, Langdon RJ, et al. Early evaluation of acute traumatic coagulopathy by 
[CONTACT_195754]. Transl Res . Jul 2009;154(1):34 -39. 
39. Jeger V, Zimmermann H, Exadaktylos AK. Can Rapi[INVESTIGATOR_392248]? J Trauma. Apr 2009;66(4):1253 -1257.  
40. Doran CM, Woolley T, Midwinter MJ. Feasibility of using  rotational thromboelastometry to assess coagulation 
status of combat casualties in a deployed setting. J Trauma. Jul 2010;[ADDRESS_492610] 1:S40 -48. 
41. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and bl ood 
transfusion in trauma patients with significant haemorrhage (CRASH -2): a randomised, placebo -controlled 
trial. Lancet. Jul 3 2010;376(9734):[ADDRESS_492611]. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. Mar 26 
2012;72(5):585 -617.  
43. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding 
trauma patients: an exploratory analysis of the CRASH -2 randomised controlled trial. Lancet. Mar 26 
2011;377(9771):[ADDRESS_492612] of tranexamic acid on mortality in patients with traumatic 
bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012;345:e5839.  
45. Effect of tranexamic ac id in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH -2 
Intracranial Bleeding Study). BMJ. 2011;343:d3795.  
46. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma 
Emergency Resu scitation (MATTERs) Study. Arch Surg. Feb 2012;147(2):[ADDRESS_492613] and the safety of aprotinin compared to 
tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg. Jan 2009;35(1) :167 -171; author reply 
171.  
48. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac 
surgery: a one -year follow -up of 1188 consecutive patients. Anesth Analg. Dec 2008;107(6):1783 -1790.  
49. Kagoma YK, Cro wther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to 
reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. 
Thromb Res. Mar 2009;123(5):687 -696.  
50. Henry D, Carless P, Fe rgusson D, Laupacis A. The safety of aprotinin and lysine -derived antifibrinolytic drugs in 
cardiac surgery: a meta -analysis. CMAJ. Jan 20 2009;180(2):183 -193.  
51. Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol. Sep 2012;92(3):[ADDRESS_492614]. Jul 2007;[ADDRESS_492615] 1:132 -142.  
53. Levy JH. Antifibrinolytic therapy: new data and new concepts. Lancet. Jul 3 2010;376(9 734):3 -4. 
54. Robertshaw HJ. An anti -inflammatory role for tranexamic acid in cardiac surgery? Crit Care. 2008;12(1):105.  
55. Jimenez JJ, Iribarren JL, Lorente L, et al. Tranexamic acid attenuates inflammatory response in 
cardiopulmonary by[CONTACT_392342]: a case control study followed by a 
randomized double -blind controlled trial. Crit Care. 2007;11(6):R117.  
56. Sander M, Spi[INVESTIGATOR_339084], Martiny V, Rosenthal C, Wernecke KD, von Heymann C. Mortality associated with 
administration of high -dose tranexamic acid and aprotinin in primary open -heart procedures: a retrospective 
analysis. Crit Care. 2010;14(4):R148.  
57. Martin K, Knorr J, Breuer T, et al. Seizures after open heart surgery: comparison of epsilon -aminocaproic acid 
and tranexamic acid. J Cardiothorac Vasc Anesth. Feb 2011;25(1):20 -25. 
58. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High -dose tranexamic acid is an independent 
predictor of early seizure after cardiopulmonary by[CONTACT_6476]. Ann Thorac Surg. Jan 2012;93(1):148 -154.  
59. Manji RA, Grocott HP, Leake J, et al. Seizures  following cardiac surgery: the impact of tranexamic acid and 
other risk factors. Can J Anaesth. Jan 2012;59(1):6 -13. 
60. Pusateri AE, Weiskopf RB, Bebarta V, et al. Tranexamic Acid and Trauma: Current Status and Knowledge Gaps 
with Recommended Research Pr iorities. Shock. Dec [ADDRESS_492616] survival for delays up to 90 minutes. The Journal of trauma. Mar 2002;52(3):420 -425.  
62. Neal M D, Peitzman AB, Forsythe RM, et al. Over reliance on computed tomography imaging in patients with 
severe abdominal injury: is the delay worth the risk? J Trauma. Feb 2011;70(2):278 -284.  
63. Howell GM, Peitzman AB, Nirula R, et al. Delay to therapeutic inte rventional radiology postinjury: time is of 
the essence. J Trauma. Jun 2010;68(6):1296 -1300.  
64. Brown JB, Stassen NA, Bankey PE, Sangosanya AT, Cheng JD, Gestring ML. Helicopters improve survival in 
seriously injured patients requiring interfacility trans fer for definitive care. The Journal of trauma. Feb 
2011;70(2):310 -314.  
65. Brown JB, Stassen NA, Bankey PE, Sangosanya AT, Cheng JD, Gestring ML. Helicopters and the civilian trauma 
system: national utilization patterns demonstrate improved outcomes after  traumatic injury. The Journal of 
trauma. Nov 2010;69(5):1030 -1034; discussion [ADDRESS_492617] combat environment: current 
concepts. The Journal of trauma. May 2003;54([ADDRESS_492618]):S43 -45. 
35 
 67. Mabry RL, Holcomb JB, Baker AM, et al. [LOCATION_002] Army Rangers in Somalia: an analysis of combat 
casualties on an urban battlefield. The Journal of trauma. Sep 2000;49(3):515 -528; discussion 528 -519.  
68. Lehmann R, Oh J, Killius S, Cornell M, Fur ay E, Martin M. Interhospi[INVESTIGATOR_392249] a combat environment: risks, adverse events, and process improvement. The Journal of trauma. Apr 
2009;66([ADDRESS_492619]):S31 -34; discussion S34 -36. 
69. Brown JB, Cohen MJ, Minei JP, et al.  Characterization of acute coagulopathy and sexual dimorphism after 
injury: Females and coagulopathy just do not mix. J Trauma Acute Care Surg. Dec 2012;73(6):1393 -1398.  
70. Reynolds BR, Forsythe RM, Harbrecht BG, et al. Hypothermia in massive transfusion:  have we been paying 
enough attention to it? J Trauma Acute Care Surg. Aug 2012;73(2):486 -491.  
71. Brown JB, Cohen MJ, Minei JP, et al. Debunking the survival bias myth: characterization of mortality during 
the initial 24 hours for patients requiring massi ve transfusion. J Trauma Acute Care Surg. Aug 2012;73(2):358 -
364; discussion 364.  
72. Neal MD, Marsh A, Marino R, et al. Massive transfusion: an evidence -based review of recent developments. 
Arch Surg. Jun 2012;147(6):563 -571.  
73. Kautza BC, Cohen MJ, Cusc hieri J, et al. Changes in massive transfusion over time: an early shift in the right 
direction? J Trauma Acute Care Surg. Jan 2012;72(1):106 -111.  
74. Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower ri sk of 
mortality after massive transfusion. J Trauma. Nov 2008;65(5):[ADDRESS_492620]. Resuscitation. Nov 2012;83(11):[ADDRESS_492621]. N Engl J Med. Sep 1 2011;365(9):[ADDRESS_492622]. N Engl J Med. Sep 1 2011;365(9):[ADDRESS_492623] of real -time feedback during cardiopulmonary resuscitation 
outside hospi[INVESTIGATOR_307]: prospective, cluster -randomised trial. BMJ. 2011;342:d512.  
79. Bulger EM, Guffey D, Guyette FX, et al. Impact of prehospi[INVESTIGATOR_392250]: a 
multicenter evaluation from the Resuscitation Outcomes Consortium. J Trauma Acute Care Surg. Mar 
2012;72(3):567 -573; discussion 573 -565; quiz 803.  
80. Guyette FX, Farrell K, Carlson JN, Callaway CW, Phrampus P. Compar ison of Video Laryngoscopy and Direct 
Laryngoscopy in a Critical Care Transport Service. Prehosp Emerg Care. Dec [ADDRESS_492624] CW, Menegazzi JJ. Variables associated with successful 
intubation attempts using vide o laryngoscopy: a preliminary report in a helicopter emergency medical service. 
Prehosp Emerg Care. Apr-Jun 2012;16(2):[ADDRESS_492625]-Dec 
2007;11(4):[ADDRESS_492626] C, Puyana JC. Prehospi[INVESTIGATOR_392251] a predictor 
of outcomes in trauma patients: a retrospective observational study. J Trauma. Apr 2011;70(4):782 -786.  
84. Guyette FX, Gomez H, Suffoletto B, e t al. Prehospi[INVESTIGATOR_392252] -
hospi[INVESTIGATOR_392253]. J Trauma Acute Care Surg. Apr 2012;72(4):[ADDRESS_492627]-Dec 
2006;10(4):[ADDRESS_492628]. Resuscitation. Dec 2004;63(3):277 -282.  
87. Sauaia A, Moore FA, Moore EE, et al. Epi[INVESTIGATOR_392254]: a rea ssessment. J Trauma. Feb 
1995;38(2):185 -193.  
88. Acosta JA, Yang JC, Winchell RJ, et al. Lethal injuries and time to death in a level I trauma center. J Am Coll 
Surg. May 1998;186(5):528 -533.  
36 
 89. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, rand omized, controlled clinical trial of transfusion 
requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care 
Trials Group. N Engl J Med. Feb 11 1999;340(6):[ADDRESS_492629] GR, Artigas A, Brigham KL, e t al. The American -European Consensus Conference on ARDS. Definitions, 
mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. Mar 1994;149(3 Pt 
1):818 -824.  
91. Sauaia A, Moore FA, Moore EE, Lezotte DC. Early risk factors  for postinjury multiple organ failure. World J 
Surg. May 1996;20(4):392 -400.  
92. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: a bimodal 
phenomenon. J Trauma. Apr 1996;40(4):501 -510; discussion 510 -502.  
93. Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A. Validation of postinjury multiple organ failure 
scores. Shock. May 2009;31(5):438 -447.  
94. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. Dec 19 
2011;208(13):2581 -2590.  
95. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. Sep 1979;35(3):[ADDRESS_492630] the following website listed: www.acutecareresearch.org  
There will be information on how to get more information about the trial and how to obtain on “opt out 
bracelet” if desired.  
C.     Surveys  
Paper s urveys will be placed in the Trauma Service outpatient clinic. They will also include the web 
address and contact [CONTACT_3031].   A deta iled telemarketing survey will be performed over a four -week 
period with approximately [ADDRESS_492631]. They will be orange  and state “NO STAAMP ”. 
 
  
38 
 Clinical Protocol Appendix 3 – Data Safety Monitoring Board (DSMB) Charter  
DSMB Charter  
 
Study of Tranexamic acid during Air and ground Medical Prehospi[INVESTIGATOR_392092] (STAAMP) trial  
 
August  03, [ADDRESS_492632] (DSMB) Overview  
Trial Description and Study Design  
• Trial name: [CONTACT_392359][INVESTIGATOR_392092] 
(STAAMP) trial  
• Principal investigator (PI): Jason Sperry, MD, MPH  
• Funding agency: Department of Defense  
• Trial design: Multi -center, prospective, randomized, blinded, controlled interventional trial.   
• Phase: III  
• Number of patients: 994  
• Number of sites: 4  
 
DSMB Description  
• This DSMB will be coordinated by [CONTACT_978], Jason Sperry, MD, MPH.  
• This DSMB will be independent of the investigators, funding agency, regulatory agencies, and 
institutional review boards.  
• This charter will  be approved by [CONTACT_392343].  
 
DSMB Membership  
• Members will disclose conflicts of interest and will be cleared of significant conflicts of interest 
and potential conflicts of interest in accordance with pr ovisions in this charter.  
• DSMB members will sign confidentiality agreements covering DSMB activities.  
• Composition of membership will be researchers with the following expertise:  hematology 
(transfusion medicine), surgery (trauma/critical care), prehospit al emergency medicine, 
epi[INVESTIGATOR_623] (clinical trial design), and biostatistician.  
• Remuneration will be provided any expenses related to DSMB activities.  
 
Reporting  
• Unblinded data to be reviewed by [CONTACT_392344].  
Issues and recommendations identified by [CONTACT_392345] [INVESTIGATOR_392255].  
• Details o f closed session deliberations (e.g., minutes) will be considered privileged and not 
subject to disclosure except as required by [CONTACT_2371].  
 
 
 40 Introduction  
The purpose of this charter is to define the roles and responsibilities of the DSMB, delineate 
qualificatio ns of the membership, describe the purpose and timing of meetings, provide the 
procedures for ensuring confidentiality and proper communication, and outline the content of the 
reports.   
 
The DSMB will function in accordance with the principles of the foll owing documents: FDA document 
“Guidance for Clinical Trial Sponsors: On the Establishment and Operation of Clinical Trial Data 
Monitoring Committees”.  
 
Study Overview/Summary  
Objective/Hypothesis: The primary hypothesis will be that prehospi[INVESTIGATOR_392256] o f tranexamic acid in 
patients at risk for bleeding will reduce the incidence of [ADDRESS_492633] -injury..  
 
Specific Aims:  
Aim#1: Determine whether prehospi[INVESTIGATOR_392099] a lower 
inciden ce of 30 day mortality, 24 hour mortality, acute lung injury, multiple organ failure, nosocomial 
infection and improved shock parameters and early resuscitation and transfusion requirements.  
 
Aim#2: Determine whether prehospi[INVESTIGATOR_392257], lowers the incidence of acute traumatic coagulopathy and improves early markers of 
coagulopathy.  
 
Aim#3: To explore novel mechanisms by [CONTACT_392301][INVESTIGATOR_392258], plasmin levels and plasmin mediated complement activation and the early cytokine 
response to trauma.  
 
Aim#4: Determine whether different dosing regimens of tranexamic ac id upon arrival in the hospi[INVESTIGATOR_392259], coagulopathy, clinical outcomes and the early 
inflammatory response.  
 
Study Design: Multi -center, prospective, randomized, blinded, controlled interventional trial over 3 
years focusing on patients with concern for bleeding who are transported via air medical transport to 
definitive care.  
 
Population: Blunt or penetrating injured patients transported via emergency medical transport  within 
two hours of injury with concern for bleeding with 1.) a documented systolic blood pressure < 90 
mmHg en route at outside/referral facility AND 2.) documented tachycardia (> 110 bpm) en route or at 
outside/referral facility..  
 
Inclusion Criteria:  
 
 
 41 1. Blunt or penetrating injured patients being transported via emergency  medical services from the 
scene of injury or from referring hospi[INVESTIGATOR_114682] a definitive trauma center that is participating in the trial  
AND  
2. Within 2 hours of time of injury  
AND  
3A. H ypotension (Systolic Blood Pressure (SBP) < 90mmHg)  
i. At scene of injury or during emergency  medical transport  
ii. Documented at referring hospi[INVESTIGATOR_392162] 
3B. Tachycardia (heart rate >110 beats per minute)  
i. At sc ene of injury or during emergency  medical transport  
ii. Documented at referring hospi[INVESTIGATOR_392260] #3. and #4. not required to be simultaneous  
 
Exclusion Criteria:  
1. Age > 90 or < 18 years of age;  
2. Inability to obtain intravenous  or intraosseous access  ; 
3. Documented cervical cord injury with motor deficit;  
4. Known prisoner;  
5. Known pregnancy;  
6. Traumatic arrest with > 5 minutes CPR without return of vital signs;  
7. Penetrating cranial injury  
8. Traumatic brain injury with brain matter exposed;  
9. Isolated drowning or hanging victims  
10. Wearing an opt out bracelet.  
11. Isolated fall from sta nding  
12. Objection by [CONTACT_392346]: The Intervention will have both a prehospi[INVESTIGATOR_392165] -hospi[INVESTIGATOR_392166]. 
Investigational Drug Services (IDS) at the University of Pi[INVESTIGATOR_392261]. IDS at the University of Pi[INVESTIGATOR_124565] a long track record of 
managing large multicenter trials and is currently execut ing and responsible for over 150 inpatient 
and outpatient clinical trials.  
Prehospi[INVESTIGATOR_392171] : Once inclusion and exclusion are verified while the patient is 
being transported via emergency  medical transport to a STAAMP trial participating cent er, in a 
randomized, double blinded fashion, either 1 gram bolus of tranexamic acid diluted in 100cc of 
normal saline (preprepared on helicopter) or placebo of identical volume will be infused into the 
patient over approximately [ADDRESS_492634] operating procedures utilizing goal directed crystalloid infusion will be followed  
 
In-hospi[INVESTIGATOR_392171] : Upon arrival, patient blood and labs will be sampled and arrival 
rapid -TEG analysis will be p erformed within first 60 minutes. After inclusion and exclusion 
criteria verification by [CONTACT_3647], in a double blinded, randomized fashion, those patients 
who received tranexamic acid in the prehospi[INVESTIGATOR_392172] 1 of 3 different dosage 
regimens:  
 
1. Standard Tranexamic acid Dosing :  1 gram infusion over 8 hours  
 
 
 42 2. Repeat Tranexamic acid Dosing :  1 gram bolus and 1 gram infusion over 8 hours  
3. Abbreviated Tranexamic acid Dosing : No further tranexamic acid to be given  
 
For intervention blind ing purposes, each patient will receive both a bolus dose (either 
tranexamic acid or placebo) and 8 hour infusion (either tranexamic acid or placebo) depending 
on the randomized dosing regimen.  
 
Placebo/Control Arm: Prehospi[INVESTIGATOR_392262] 100cc of normal saline and infused over 10 minutes. Patients who received prehospi[INVESTIGATOR_392263] -hospi[INVESTIGATOR_392264] 8 hour placebo infusion for blinding 
purposes  
 
Rando mization: The randomization scheme will have both a prehospi[INVESTIGATOR_392165] -hospi[INVESTIGATOR_392166].  
Prehospi[INVESTIGATOR_392265] : Individual patients meeting criteria while en route via 
emergency  medial transport will be randomized using an allocation sequence  block size of 8 to 
either 1 gram of tranexamic acid or placebo diluted in 100cc of normal saline given over 10 
minutes. A single prehospi[INVESTIGATOR_392266] (1 -8) 
treatment packs (randomized with a computer random nu mber generator) will be on board 
each respective emergency transport vehicle . In an ascending numerical order fashion 
treatment packs will be utilized for enrolled patients. The box and treatment pack # will be 
recorded by [CONTACT_392347] a ll randomized patients. The patient and all 
treatment and research staff will be blinded to the treatment arm. All intervention vials will be 
covered to obscure view of vial contents to prehospi[INVESTIGATOR_392267] w ill be utilized to maintain blinding. IDS at the University of Pi[INVESTIGATOR_392268]. Additionally, the pharmacy at each respective 
participating center will have access to the prehospi[INVESTIGATOR_392269]/assignment sch eme 
once the prehospi[INVESTIGATOR_392270] # are provided to them by [CONTACT_392348].  
In-hospi[INVESTIGATOR_392187] : Using a web based, randomization assignment program built 
specifically for the trial,  research staff will provide and input the prehospi[INVESTIGATOR_392271] # 
and treatment pack # into the web based platform at each site and be provided the In -hospi[INVESTIGATOR_392272]. IDS at the Univer sity of 
Pi[INVESTIGATOR_392273] -hospi[INVESTIGATOR_392191]. The 
accepting research staff and pharmacy will verify they have the same in -hospi[INVESTIGATOR_392274]. An allocation 
sequence based upon a block size of 9 again generated with a computer random number 
generator will be utilized for those who received prehosp ital Tranexamic Acid. Each respective 
IDS or pharmacy will prepare the inhospi[INVESTIGATOR_392194] (10 minute and 8 hour infusion). 
The patient and all treatment and research staff will be blinded to the treatment that is 
received.  
 
Blinding: The trial is a  double blinded trial for both the prehospi[INVESTIGATOR_392165] -hospi[INVESTIGATOR_392195]. The participants, investigators, research coordinators and staff, and persons having 
any contact [CONTACT_392325]. The  IDS at the 
University of Pi[INVESTIGATOR_392275] 
 
 
 43 provided to them by [CONTACT_3647]. Both IDS at the University of Pi[INVESTIGATOR_392276].  
 
Roles and Responsibilities  
DSMB Roles and Responsibilities  
This DSMB will  
• Meet periodically (see DSMB Meetings) to review aggregate and individual subject data 
related to safety, data integrity and overall conduct of the trial.  
• Review specific interim analyses for efficacy (see Study Review Criteria/Stoppi[INVESTIGATOR_392277]).  
• Provide recommendations to continue or terminate the trial depending upon these 
analyses.   
• Communicate other recommendations or concerns as appropriate.  
• Operate according to the procedures described in this charter and all procedures of the 
DSMB.    
• Follow conflict of interest g uidelines as detailed below (see DSMB Membership).  
• Comply with confidentiality procedures as described below (see Confidentiality).  
• Maintain documentation and records of all activities as described below (see DSMB 
Meetings, DSMB Reports).  
 
Principal Invest igator (or Designees) Roles and Responsibilities  
The PI [INVESTIGATOR_392278]:  
• Assure the proper conduct of the study.  
• Assure collection of accurate and timely data (monitoring and data management).  
• The PI [INVESTIGATOR_392279].  
• Promptly report potential safety concern(s) to the DSMB.  
• Prepare summary reports of relevant data for the DSMB. (This may include analyses not 
otherwise outlined in this charter based upon findings.)  
• Provide an independent facilitator for presentation of results during DSMB meetings if 
requested by [CONTACT_4318].  
• Communicate with regulatory authorities, IRB, and investigators, in a manner that 
maintains integrity of the data, as necessary. (This communicati on is not the responsibility 
of the DSMB.)  
• Provide funding for the study and DSMB.  
• PI [INVESTIGATOR_392280].  
 
DSMB Membership  
The DSMB will consist of at least [ADDRESS_492635] been selected by [CONTACT_978] [INVESTIGATOR_392281].  
As characteristic qualifications, members will:  
• Work professionally and meet qualifications for their respective professions.  
• Comply with accepted practices of their respective professions.  
• Comply with the conflict of i nterest policies specified by [CONTACT_392349] 
(SOPs) of the PI [INVESTIGATOR_392282] m embers do not have serious scientific, financial, personal, or 
other conflicts of interest related to the conduct, outcome, or impact of the study according to  
 
 
 44 the guidelines specified below (e.g., engaged in any simultaneously occurring competitive trials 
in any role that could pose a conflict of interest for this study ).  
• Be independent from the PI, IRB, regulatory agencies, principal investigator, co -principa l or 
sub-principal investigator, site investigator, site sub -investigator, clinical care of the study 
subjects , or any other capacity related to trial operations.  
• Not be on the list of Notice of Initiation of Disqualification Proceedings and Opportunity to  
Explain (NIDPOE) (http://www.fda.gov/foi/nidpoe/default.html) and/or debarred list of 
investigators (http://www.fda.gov/ora/compliance_ref/debar).  
Although each DSMB member will be expected to serve for the duration of the trial, in the unlikely 
event tha t a member is unable to continue participation, the reason will be documented and a 
replacement will be selected by [CONTACT_978].  
 
The DSMB will follow conflict of interest guidelines referenced by [CONTACT_253182], Financial Relations hips and Interests in Research Involving Human Subjects: 
Guidance for Human Subject Protection ( http://www.hhs.gov/ohrp/humansubjects/finreltnn/fguid.pdf ). 
DSMB members will sign a n on-conflict of interest statement in regard to this study which will be on 
file with the PI. As determined by [CONTACT_978], conflicts of interest and/or potential conflicts of interest (as 
determined by [CONTACT_201554]) will be reduced to the greatest extent that is consis tent with assembling a 
highly competent DSMB. Any questions or concerns that arise regarding conflicts of interest will be 
addressed by [CONTACT_392350] [INVESTIGATOR_363379].  
 
DSMB Meetings  
Projected Schedule of Meetings  
An initial meeting of the DSMB will be held prior to any subject enrollment in the study in order for the 
members to review the charter, to form an understanding of the protocol and definitions being used, 
to establish a mee ting schedule, and to review the study modification and/or termination guidelines. 
Subsequent interim and final review meetings will be held to review and discuss interim and final 
study data (adverse events, protocol deviations, enrollment summary and tab les for overall primary 
and secondary endpoints).  Frequency of meetings will be every six months, unless the board 
determines otherwise.  
 
Meeting Format  
DSMB meetings will generally be conducted by [CONTACT_392351]. A quorum, 
defined as [ADDRESS_492636] ricted to the DSMB members. A facilitator or recorder may be 
requested by [CONTACT_4318]. Data which may compromise the integrity of the study (e.g., comparative 
 
 
 45 data) will be analyzed and discussed only in the closed session. The minutes of the closed session 
will be recorded by [CONTACT_45453]. Minutes from the closed session will be recorded separately 
from the minutes of the open session and stored securely by [CONTACT_45453]. Closed session 
minutes, finalized by [CONTACT_392352], will be maintained  in confidence and retained until 
discarded in accordance with applicable statutory regulation.  
 
Following each meeting, a report separate from the minutes of the open and closed sessions will be 
sent to the PI [INVESTIGATOR_392283] (see DSMB 
Communication of Findings and Recommendations).  
 
Study Review Criteria/Stoppi[INVESTIGATOR_392284], and guidelines / stoppi[INVESTIGATOR_392285]’s f irst evaluation of data.  
 
Safety Analyses  
The primary safety endpoint is mortality as observed during interim analysis.  In addition to the 
primary safety endpoint, the DSMB will monitor the following adverse events:  
1. Acute Lung Injury  
2. Nosocomial infection  
3. MOF (multiple organ failure)  
4. Early seizures  
5. In-hospi[INVESTIGATOR_392152]  
6. Blood and blood component transfusion and resuscitation requirements  
7. Adverse Events  
8. Unexpected Adverse Events  
9. Expected Adverse Events  
 
Stoppi[INVESTIGATOR_130] / Stoppi[INVESTIGATOR_1869] : Safety  
Termination or modification may be recommended for any perceived safety concern based on clinical 
judgment, including but not limited to a higher than anticipated rate for any component of the primary 
endpoint resulting in adverse events, or unexp ected SAEs.  
 
Efficacy Analyses  
The primary outcome variable 30 day mortality will be utilized to access for efficacy of the trial. 
Accessing this primary outcome variable at each interim analysis will allow early termination of the 
trial for either lack of  efficacy or excessive efficacy.  
 
Adaptive Protocol Modification  
There is no planned sample size re -estimation; however if the DSMB reveals a need, the sample size 
calculation can be re -evaluated.  
 
Consideration of External Data  
The DSMB will also conside r data from other studies or external sources during its deliberations, if 
available, as these results may have a profound impact on the status of the patients and design of the 
current study.  
 
DSMB Reports  
Monitoring for Safety  
 
 
 46 The primary charge of the DSMB is to monitor the study for patient safety. Formal DSMB safety 
reviews will occur as specified above (see Study Review Criteria/Stoppi[INVESTIGATOR_392286]).   
 
Monitoring for Efficacy  
The DSMB will monitor efficacy outcome s to determine relative risk/benefit, futility, or for early 
termination due to overwhelming efficacy.  Interim analyses efficacy reports sent to the DSMB will 
occur as specified above (see Study Review Criteria/Stoppi[INVESTIGATOR_392286]).  
 
Monitoring  for Study Conduct  
The DSMB will review data related to study conduct. Data to be reviewed and listed in the DSMB 
reports includes: enrollment rates over time, time from last patient enrolled to date of report 
(indication of delay between treatment or foll ow-up and reporting), summary of protocol violations, 
and completeness of treatment and follow -up visit data.  
 
Data Flow for Adverse Events  
The DSMB will carefully monitor adverse events periodically throughout the duration of the study. 
This process will be dynamic to include quarterly reviews of all reported SAEs by [CONTACT_392353]. The investigators will be expected to report Serious Adverse Events (SAEs) to the PI 
[INVESTIGATOR_874] [ADDRESS_492637] recent data (recognizing limitations thereof) available at the time of the analysis. Requests for 
additional data by [CONTACT_392354], 
who will be responsible for communicating the request with th e PI. 
 
The DSMB will review the data and discuss the analyses during the closed portion of the scheduled 
meeting.   If in the closed session the DSMB finds blinded results that are concerning, the meeting will 
be ended and the DSMB will reconvene in closed session within 1 week to be given the same data 
unblinded.  If the meeting is necessary, an additional interim analysis will be added to the two 
scheduled interim analyses resulting in the need to recalculate alpha spent.  We will be cognizant of 
the logis tical and scientific costs associated with this plan when we are considering any unscheduled 
analysis.  
 
For the interim analyses at 1/3 and 2/3 enrollment points, the biostatistician will create two reports for 
the DSMB closed session meeting: one with the  treatment arms blinded and one with the blinds 
broken.  The biostatistician will first present to the DSMB data with the blinds intact in closed session.  
If no point estimates are within the range of the a priori  stoppi[INVESTIGATOR_004], the statistician will be asked to 
proceed at that time with presenting a report with the blinds broken.  As the alpha accounting for 
these two interim looks has already been calculated, it will not need to be recalculated.  
 
DSMB Communication of Findings and Recommendations  
 
 
 47 Following each meeting and within 14 days of the meeting, the chairperson will send findings and 
recommendations of the DSMB in writing to the PI.  
 
These findings and recommendations can result from both the open and closed sessions of the  
DSMB. If these findings include serious and potentially consequential recommendations that require 
immediate action, the chairperson will also promptly notify the PI [INVESTIGATOR_392287]/or by [CONTACT_6968].  
 
PI’s Response to DSMB Findings and Recommendations  
The PI [INVESTIGATOR_6254]-investigators will review and respond to the DSMB recommendations. The 
recommendations of the DSMB will not be legally binding but require professional consideration by 
[CONTACT_1955][INVESTIGATOR_840]. If the DSMB recommends continuation of the study without modificatio n, no formal 
response will be required. However, if the recommendations request action, such as a 
recommendation for termination of the study or modification of the protocol, the DSMB will request 
that the PI [INVESTIGATOR_392288] a formal written response stating wheth er the recommendations will be followed 
and the plan for addressing the issues.  
 
It is recognized that the PI [INVESTIGATOR_392289]. Upon receipt, the DSMB will consider  the PI [INVESTIGATOR_392290], resulting in a final decision. Appropriate caution will be necessary 
during this process to avoid compromising study integrity or the ability of the PI [INVESTIGATOR_392291], 
should the study cont inue. The PI [INVESTIGATOR_392292], IRB, and investigators within an appropriate time.  
 
In the unlikely event of irreconcilable differences, especially regarding study termination or other 
subst antial study modifications, the DSMB may decide to discontinue monitoring the current study 
and disband. This decision will be communicated to the PI, FDA, and IRBs.  
 
Public disclosure of the PI’s final decision or DSMB recommendations will be at the discr etion of the 
PI [INVESTIGATOR_7516]. The DSMB will not make any public announcements either as a group or 
individually.   
 
DSMB Closeout  
This study may be terminated under a variety of circumstances including, but not limited to, 
termination for overwhelming  effectiveness, futility, or safety issues per protocol or DSMB monitoring 
guidelines. Responsibilities of the DSMB with regard to closeout will be to review the final study report 
to ensure study integrity. The DSMB may recommend continuing action items t o the PI [INVESTIGATOR_392293].  
 
Confidentiality  
All data provided to the DSMB and all deliberations of the DSMB will be privileged and confidential. 
The DSMB will agree to use this information to accomplish the responsibilities of the DSMB and will 
not use it for other purposes without written consent from the study PI [INVESTIGATOR_6254] -investigators. No 
communication of the deliberations or recommendations of the DSMB, either written or oral, will occur 
except as required for the DSMB to fulfill its responsibi lities. Individual DSMB members must not have 
direct communication regarding the study outside the DSMB (including, but not limited to the 
investigators, IRB, regulatory agencies, or PI) except as authorized by [CONTACT_4318].  
 
 
 
 48 Amendments to the DSMB Charter  
This DSMB charter can be amended as needed during the course of the study. Information to be 
included as amendments will be any modifications or supplements to the reports prepared for the 
DSMB, as well as amendments to other information addressed in this cha rter. All amendments will be 
documented with sequential version numbers and revision dates, and will be recorded in the minutes 
of the DSMB meetings. Each revision will be reviewed and agreed upon by [CONTACT_392355] [INVESTIGATOR_392294]. All versions of the char ter will be archived in accordance with this document and maintained 
by [CONTACT_978].  
 
  
 
 
 49 Clinical Protocol Appendix 4 – Stoppi[INVESTIGATOR_392295], prior to initiation of the trial, the final monitoring plan will be developed to serve as the guide 
to the DSMB’s decision -making process concerning early stoppi[INVESTIGATOR_392296].  In making 
the decision to recommend termination of the study, the DSMB shall be guided by [CONTACT_392339]: (i) a 
formal stoppi[INVESTIGATOR_392235] (comparison of treatment groups on the 30 day mortality), (ii) 
information on safety outcomes by [CONTACT_1570], (iii) consistency between results for primary and secon dary 
outcomes, and (iv) consistency of treatment effects across subgroups.  
1. O'Brien -Fleming  spending (z -values and related alpha) of interim boundaries for each look  
We have designed this trial with a two interim look before the final analysis. Our power an alysis generated assuming a 
total of 3 sequential tests based on O'Brien -Fleming spending function to determine alpha spending and test boundaries. 
We will use test of proportions differences, two sided z -test with continuity correction applied and other a djusting 
techniques. The level of significance will maintain an overall p value of 0.05 according to O’Brien -Fleming stoppi[INVESTIGATOR_392297] a p value of 0.038; two sided, for the final analysis with a final z -value of 1.993. An independent data 
and sa fety monitoring board (DSMB) will periodically review the efficacy and safety data. DSMB will issue related 
recommendations based on comprehensive data monitoring and substantiated evidences. Two formal interim analyses of 
efficacy will be performed when 3 3% and 67% of the expected number of primary events had accrued (about one month 
after 1/3 and 2/[ADDRESS_492638] accruals). The purpose of our sequential tests is to detect early sign of superior efficacy and 
detect further apparent futility in the interventi on group. This kind of futility monitoring and testing could cause this trial 
to be stopped as soon as a negative outcome of [ADDRESS_492639] of trials that ultimately provides negative answers regarding the 
value of the study medical intervention.  
 
Our trial’s lower and upper stoppi[INVESTIGATOR_392298] I and Type II error 
probabilities of the group sequential plan are according to the study assumptions and design. The upper boundaries are 
related to the formal efficacy testing at each assigned s ample size (expected number of primary events completion at 
33%, 67%, and 100%). The lower boundaries are related to the formal futility (safety) testing at each assigned sample 
size (expected number of primary events completion at 33%, 67%, and 100%). Upp er and lower boundaries will be 
provided to DSMB as a guideline and could be modified by [CONTACT_392356]. With this 
sequential testing plan based on O'Brien -Fleming spending function, only an absolutely overwhelming t reatment 
intervention can justify the termination of our clinical trial after a third of the subjects have been enrolled and completed  
a one month of follow up. If the trial has been ordered to stop early because of interim analysis, adjusted p -values will  be 
computed based on the described analysis of our main clinical outcome. Unadjusted p -value will not be considered for 
final results interpretations.  
Our interim analysis is part of our three sequential testing as we have mentioned above. At each of the  two interim looks, 
[ADDRESS_492640] illustrated z -values for the upper and lower boundaries across interim 
two analyses and final analysis of a total accumulated alpha of  0.05. (Figure and Table below)  
Details when Spending = O'Brien -Fleming, N1  = 497, N2 =497, P1 = 0.10, P2 = 0.16  
  Lower  Upper  Nominal  Inc Total  Inc Total 
Look  Time  Bndry  Bndry  Alpha  Alpha  Alpha  Power  Power  
1 0.33 -3.[ZIP_CODE]  3.[ZIP_CODE]  0.000207  0.000207  0.000207  0.018687  0.018687   
2 0.67 -2.[ZIP_CODE]  2.[ZIP_CODE]  0.012025  0.011890  0.012097  0.399207  0.417894   
 
 
 50 3 1.00 -1.[ZIP_CODE]  1.[ZIP_CODE]  0.046259  0.037903  0.050000  0.382494  0.800388   
Drift 2.[ZIP_CODE]  
 
Look: These are the sequence numbers of the interim tests.  
 
Time: These are the time points at which the interim tests are conducted. This is also related to proportion of subject accruals  
 
Lower and Upper Boundary: These are the test boundaries. If the computed value of the test statistic z is between these values, the trial should 
continue. Otherwise, the trial can be stopped.  
 
Nominal Alpha:  This is the value of alpha for these boundaries if they were used for a single, standalone test. Hence, this is the significa nce level 
that must be found for this look in a standard statistical package that does not adjust for multiple looks.  
 
Inc Alpha:  This is the amount of alpha that is spent by [CONTACT_392340]. It is close to, but not equal to, the value of alpha that would be achieved if 
only a single test was conducted. The difference is due to the correction that must be made for multiple tests.  
 
Total Alpha: This is the total amount of alpha that is used up to and including the current test.  
 
Inc Power: These are the amounts that are added to the total power at each interim test. They are often called the exit probabilities be cause they give 
the probability that significance is found and the trial is stopped, given the alternative hypothesis.  
 
 
O’Brien -Fleming boundary values are inversely proportional to the square root of information levels on the standardized  Z scale 
(O’Brien and Flemi ng 1979). The O’Brien -Fleming boundary is conservative in the early stages and tends to stop the trials early only 
with a small  P-value. But the nominal value at the final stage is close to the overall  P-value of the design.  
 
 
The above plot shows the interim boundaries for each look. This plot shows very dramatically that the results must be 
extremely significant at early looks, but that they are near the single test boundary (1.96 and -1.96) at the last look.  
References  
1. Chow, S.C.; Shao, J.; Wang, H. 2003. Sample Size Calculations in Clinical Research. Marcel Dekker. [LOCATION_001].  
2. Lan, K.K.G. and DeMets, D.L. 1983. 'Discrete sequential boundaries for clinical trials.' Biometrika, 70, pages 659 -663. 
3. O'Brien, P.C. and Fleming, T.R. 1979. 'A multiple  testing procedure for clinical trials.' Biometrics, 35, pages 549 -556 
4. Pocock, S.J. 1977. 'Group sequential methods in the design and analysis of clinical trials.' Biometrika, 64, pages 191 -199 
O'Brien-Fleming Boundaries with Alpha = 0.05
Upper
LowerZ Value
Look-1
-2
-3
-401234
0.5 1.0 1.5 2.0 2.5 3.0
 
 
 51 5. Reboussin, D.M., DeMets, D.L., Kim, K, and Lan, K.K.G. 1992. ' Programs for computing group sequential boundaries using the Lan -
DeMets Method.' Technical Report 60, Department of Biostatistics, University of Wisconsin -Madison.  
. 
2. Eligibility, recruitment, and accrual reporting  
Our periodic reports to DSMB will include  as well data on recruitment, data completion, data quality, etc. Data will be 
summarized in tables as listed below of simplicity and clarity.  For simplicity and clarity in reading information, data on 
eligibility, recruitment, and accrual reporting will b e summarized in table 1 and figure 1 and 2.  
 
    Table 1 Recruitment and Accrual  
 Center1  Center2  Center3  Center4  Center5  Total  
Study treatment  A B A B A B A B A B A B 
Duration of time 
in weeks since 
start going life              
Number of 
Patients 
screened              
Number of 
patient eligible 
for study              
Eligible but not 
entered in the 
study              
Drop off / not 
able to follow up              
Total patient 
“randomized”              
Average accrual 
per month              
Data completion 
(✓) 
             
Data Quality ( ✓) 
             
 
 
 
 
 
 
 
 
 
 
 
 [ADDRESS_492641] Interim Analysis
 
 
 53 3. Information on subjects’ demographics and illnesses  
In details information on subjects’ demographics and illnesses will be summarize in table 2  
Table 2 Demographics and Baseline Disease Characteristics  
 Center1  Center2  Center3  Center4  Center5  Total  
 A B A B A B A B A B A B 
Patients 
numbers              
Age, median and 
range              
Sex (male) n (%)              
Race, N (%)  
White  
Black  
Other              
Average Lowest 
pre hospi[INVESTIGATOR_392299] (blunt) 
(%)             
CPR (%)              
Pre hospi[INVESTIGATOR_392300] (%)              
!!!             
 
4. Monitoring Safety and efficacy  
Further and in relation to interim safety analysis, safety data by [CONTACT_392357] (Early 
using of tranexamic acid ) and Control group (Standard of care) will be provided periodically to DSMB. These processed 
data will provide i nformation on safety outcomes by [CONTACT_1570], ascertain the consistency between results for 
primary and secondary outcomes, and inspect the consistency of treatment effects across subgroups.  Safety data of the 
study include serious adverse events rega rding frequency, anticipated or unanticipated, individual description for each 
event and dates. Other data will be provided as well as any additional safety analysis upon DSMB request. Mortality will 
be reported as an overall in our periodic reports (every  6-9 months depends on accrual rate) to DSMB however we will 
report mortality individually as treatment A and B at each of the trial two formal interim analyses. Data will be 
summarized in tables (3 -6) 
 
 
 
 54  
Table 3 Possible Adverse effects  
 Center1  Center2  Center3  Center4  Center5  Total  
 A B A B A B A B A B A B 
Patients 
numbers              
Transfusion 
related lung 
injury n, (%)              
Allergic/anaphyl
actic reaction              
Circulatory 
overload              
Infection              
Febrile reaction              
Hemolytic 
reaction              
!!!             
!!!             
!!!!             
 
Table 4 Unexpected Adverse Effects  
 Center1  Center2  Center3  Center4  Center5  Total  
 A B A B A B A B A B A B 
Patients 
numbers              
1.                  n,(%)              
2.             
3.             
4.             
             
             
 
Table 5 Primary outcomes for patients in the Study  
 Center1  Center2  Center3  Center4  Center5  Total  
 A B A B A B A B A B A B 
Number of 
Patients              
24 hr Mortality 
n, (%)              
30 day Mortality 
n, (%)              
 
Table 6 Secondary outcomes for patients in the Study  
 Center1  Center2  Center3  Center4  Center5  Total  
 
 
 55  A B A B A B A B A B A B 
Number of Patients              
Hyperfibrinolysis              
Acute lung injury (%)              
Multiple organ failure 
(%)              
Nosocomial infection (%)              
Improved shock 
parameters (%)              
Early resuscitation need 
(%)              
Transfusion 
requirements (%)              
Early seizures (%)              
Pulmonary embolism (%)              
Reduce or prevent the 
early coagulopathy as 
demonstrated by 
[CONTACT_392358] (%)              
and Rapid 
thromboelastography 
parameters (%)              
Reduce the early 
inflammatory response, 
plasmin levels, leukocyte, 
platelet and complement 
activation (%)              
ICU days              
Ventilation days              
Hospi[INVESTIGATOR_95156]              
!!!             
 